

## **Lisa A. Prosser, PhD**

Marilyn Fisher Blanch Professor of Pediatrics  
University of Michigan  
NCRC Bldg 16, G031N  
2800 Plymouth Rd, Ann Arbor MI 48109  
(617) 312-3865; lisapros@umich.edu

### **Education and Training**

#### ***Education***

- 08/1984-05/1988 BA, Mathematics (Concentration: Operations Research), Cornell University, Ithaca, NY
- 09/1990-06/1992 MS, Management, MIT Sloan School of Management, Cambridge, MA
- 09/1990-06/1992 MS, Technology & Policy, Massachusetts Institute of Technology, Cambridge, MA
- 09/1995-06/2000 PhD, Health Policy (Concentration: Decision Sciences), Harvard University, Cambridge, MA

#### ***Additional Training***

- 09/1987-12/1987 Semester Abroad, Queen Mary College, University of London, London, United Kingdom
- 01/2003 AAMC Early Career Women Faculty Professional Development Seminar, Santa Fe, NM
- 01/2010 University of Michigan Masters Series Leadership Program, Ann Arbor, MI
- 05/2011 Linkage Leadership Academy, Ann Arbor, MI
- 12/2015 AAMC Mid-Career Women Faculty Professional Development Seminar, Austin, TX
- 08/2016 Executive Coaching- Master Coaching Certification Training, Ann Arbor, MI
- 6/2021-5/2022 Executive Leadership in Academic Medicine (ELAM), Drexel University, PA

### **Academic, Administrative, and Research Appointments**

#### ***Academic Appointments***

- 07/1999-06/2000 Fellow, Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, MA
- 07/2000-03/2001 Instructor, Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, MA
- 04/2001-05/2009 Assistant Professor, Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, MA
- 02/2006-06/2009 Assistant Professor (secondary), Department of Health Policy and Management, Harvard School of Public Health, Boston, MA
- 10/2008-12/2008 Visiting Research Associate Professor in Pediatrics, University of Michigan, Ann Arbor, MI
- 10/2008-06/2012 Lecturer, Department of Population Medicine (formerly Department of Ambulatory Care & Prevention), Harvard Medical School, Boston, MA
- 10/2008-08/2016 Adjunct Associate Professor, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA
- 09/2016-06/2022 Adjunct Professor, Department of Health Policy and Management, Harvard T.H Chan School of Public Health, Boston, MA
- 09/2016-present Professor (with tenure), Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI

09/2016-present Professor (joint), Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, MI

### **Administrative Appointments**

01/2008-05/2010 Affiliated Faculty, Pediatric Health Services Research Fellowship Program, University of Michigan, Ann Arbor, MI

10/2008-present Core Faculty, Child Health Evaluation and Research Center, Division of General Pediatrics, University of Michigan, Ann Arbor, MI

01/2010-present Member, Doctoral Program in Health Services Organization and Policy (HSOP) Committee, University of Michigan School of Public Health, Ann Arbor, MI

09/2010-present Core Faculty, Decision Sciences and Operations Research Cognate, PhD Program in Health Services Organization and Policy, University of Michigan School of Public Health, Ann Arbor, MI

01/2011-07/2015 Affiliated Faculty, Risk Science Center, University of Michigan School of Public Health, Ann Arbor, MI

01/2011-01/2016 Core Faculty, Pediatric Health Services Research Fellowship Program, University of Michigan, Ann Arbor, MI

01/2013-06/2015 Director of Faculty Development, Office of Faculty Affairs, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI

01/2013-present Faculty Coordinator, Modeling Health and Economic Outcomes Working Group (MHEO), University of Michigan, Ann Arbor, MI

07/2013-06/2015 Interim Director, Child Health Evaluation and Research Unit, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI

07/2015-06/2023 Director, Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI

01/2018-01/2019 Senior Faculty Advisor to the Early Career Faculty Development Council, Institute for Healthcare Policy and Innovation, Ann Arbor, MI

02/2019-12/2021 Assistant Dean for Research Faculty, University of Michigan Medical School, Ann Arbor, MI

07/2019-09/2022 Director, Pediatric Health Services Research Fellowship Program, University of Michigan, Ann Arbor, MI

01/2020-09/2022 Director, CHEAR-LSI Child Health Policy Scholars Program, University of Michigan, Ann Arbor, MI

09/2021-present Associate Vice President for Research-Health Sciences, University of Michigan Office of the Vice President for Research, Ann Arbor, MI

### **Research Positions**

11/1996-06/2000 Research Assistant, Program for the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA

01/2008-09/2008 Research Scientist, Center for Health Services Research, Henry Ford Health System, Detroit, MI

### **Research Interests**

My research focuses on the evaluation of public health interventions for children and adults using methods of decision sciences and economics. Research topics include: evaluating the cost-effectiveness of prevention programs, assessing long-term health and economic outcomes for newborn screening programs using simulation modeling, and measuring public values relevant to health decisions. My methodological research focuses on

methods of cost-effectiveness analysis for pediatric interventions, economic spillover effects of illness on the family, and family well-being

## Grants

### Current Grants

*T76 MC54775 Center of Excellence in MCH Education, Science and Practice Program*

Maternal and Child Health Bureau/HHS

Co-I with effort (Principal Investigator: Kendrin Sonnevile)

06/2025-05/2030. \$1,832,860

*U01 IP001198 Preferences and Values for Vaccine Economics (PAVVE)*

Centers for Disease Control and Prevention

Lisa Prosser, PI

09/2023-08/2026. \$1,200,000

*U24 FAMILY WELL-BEING RESEARCH NETWORK ("FAM-NET"): Measuring Family Well-Being across the Lifespan*  
NIH

Lisa Prosser, Contact PI (MPIs: Eve Wittenberg, Harvard; Janel Hanmer, University of Pittsburgh)

06/2021-05/2026. \$2,544,006

### Past Grants

*K23 HD105987 Developing a user-centered novel online sexual health curriculum for adolescent girls with physical disabilities*

NIH

Co-mentor without effort (Principal Investigator: Courtney Streur)

09/2022-08/2025. \$508,680

*RSV Modeling, Cost Assessments, and Health Utility Analyses*

Centers for Disease Control and Prevention

Lisa Prosser, PI

09/2022-03/2025 \$250,000

*HRSA MCHB IDIQ to Support the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC)*

HRSA/MCHB

Lisa Prosser, Site PI

10/2020-01/2025. \$1,602,816

*K08 DA048110-05: Using Default Opioid Prescription Settings to Limit Excessive Opioid Prescribing to Adolescents and Young Adults*

NIDA

Co-I without Effort (Principal Investigator: Kao-Ping Chua)

05/2019-04/2024. \$911,520

*Development and Validation of a Preference-Based Index for the PEDS-QL*

PhRMA Foundation 20-PAF01522

Lisa Prosser, PI

01/2020-11/2023. \$100,000

*UG3 DA050173-01: Optimized Interventions to Prevent Opioid Use Disorder among Adolescents and Young Adults in the Emergency Department*

NIH

Co-I with Effort (Principal Investigator: Maureen A Walton)

08/2020-07/2022. \$699,050

*R01 HD097107-05: Using Re-enforcement Learning to Automatically Adapt a Remote Therapy Intervention (RTI) for Reducing Adolescent Violence Involvement*

NIH

Co-I with Effort (Principal Investigator: Patrick Michael Carter)

09/2018-08/2023. \$3,899,860

*K01 DA044279: Preventing substance use among youth: behavioral and economic impact of enhanced implementation strategies for communities*

NIDA

Co-I without Effort (Principal Investigator: Andria Eisman)

01/2019-12/2022

*Joint Initiative in Vaccine Economics, Phase 6*

CDC

Lisa Prosser, PI

09/2018-08/2022. \$900,000

*R24 HD087149: Building Research Capacity for Firearm Safety among Children*

NIH

Co-I with Effort (Principal Investigator: Marc Zimmerman/Rebecca Cunningham)

03/2018-08/2022

*K01 AI137123: Characterizing parental beliefs to support optimization of vaccine introduction*

NIAID

Co-I without Effort (Principal Investigator: Abram Wagner)

01/2018-01/2023

*U01 DE021412: Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings*

NIH

Co-I with Effort (Principal Investigator: Margherita Fontana)

01/2018-05/2022

*R01 HD086583-05: Decision-Making for Patients Born with Differences of Sex Development (DSD)*

NIH

Co-I with Effort (Principal Investigator: David Eric Sandberg)

09/2016-06/2022. \$2,608,097

*R01 CA21482903: The Lifecycle of Health Data: Policies and Practices*

NIH

Co-I with Effort (Principal Investigator: Sharon Reilly Kardia)

02/2018-01/2022. \$2,446,187

*R01 HD092594: Tiny Cargo, Big Deal! An Adaptive ED-Based eHealth Intervention to Promote Correct and Consistent Size-Appropriate Child Passenger Safety Behaviors and Reduce Disparities*

Lurie Children's Hospital/NIH

Co-I with Effort (Principal Investigator: Michelle Macy)

01/2018-12/2021

*R01 HD093611: Technology-Based Intervention for Reducing Sexually Transmitted Infections and Substance Use During Pregnancy*

NIH

Co-I with Effort (Principal Investigator: Golfo Tzilos Wernette)

01/2018-12/2021

*The COVID Modeling Accelerator: From Decision Models to Practical Uses*

Rockefeller Foundation through a consortium with Johns Hopkins University

Lisa Prosser, Site PI

09/2020-04/2022. \$39,205

*HRSA MCHB TASK ORDER (FY18) to Support the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC)*

HRSA/MCHB

Lisa Prosser, Site PI

03/2020-09/2021. (\$20,105)

*SMDM COVID19 Modeling Grants Program-Catalyzing Immediate Impact Where Needed*

Gordon and Betty Moore Foundation

Lisa Prosser, Kathy McDonald (JHU), Gillian Sanders Schmidler (Duke), Co-PIs

05/2020-09/2021. \$500,000

*75D 30121P10141: RZV - Risk-Benefit Analysis*

Centers for Disease Control and Prevention

Lisa Prosser, PI

12/2020-06/2021. \$30,979

*Michigan Center for Diabetes Translational Research*

NIH

Co-I with Effort (Principal Investigator: Herman, William)

07/2016-06/2021. \$2,712,500

*K01 HL132057: Identifying opportunities to improve hydroxyurea therapy initiation and adherence among children with sickle cell disease*

NHLBI

Co-I without Effort (Principal Investigator: Sarah Reeves)

03/2016-12/2021

*K07 CA200668: Patient preferences and adherence in adolescents and young adults with cancer*

NCI

Other (Principal Investigator: Meghan McGrady)

01/2016-12/2021

*K08 HS024599: Determining tradeoffs among health benefits, adverse events, and resource use associated with food allergy treatment*

AHRQ

Co-I without Effort (Principal Investigator: Matthew Greenhawt)

01/2016-12/2020

*P30 DK092926-10: MCDTR and UNC-Chapel Hill - Peer Support Core*

NIH

Co-I with Effort (Principal Investigator: William H Herman)

09/2011-07/2021. \$2,881,292

*HRSA MCHB TO5 Implementation of Newborn Screening Timeliness and SMA to Support the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC)*

HRSA/MCHB

Co-I with Effort (Principal Investigator: Alex Kemper)

01/2018-12/2020

*R01 DK109995: Population Health Impact of a Self-Insured Employer's Policy Change to Cover Weight Reduction and Diabetes Prevention Interventions for Employees, Dependents, and Retirees with Prediabetes*

NIDDK

Co-I with Effort (Principal Investigator: William Herman)

01/2016-12/2020

*Michigan Section 298 Pilot Demonstration Evaluation*

MDHHS

Co-I with Effort (Principal Investigator: Kara Zivin)

11/2017-10/2020. \$1,299,948

*Evidence based review on Spinal Muscular Atrophy (SMA) for Secretary's Discretionary Advisory Committee on Heritable Disorders in Newborns and Children (DACHDNC)*

HRSA/MCHB

Lisa Prosser, Site PI

07/2017-06/2018. \$89,762

*Center for Valuing Child Health (Planning Grant)*

PhRMA Foundation-17-PAF08111

Lisa Prosser, PI

05/2017-08/2017. \$25,000

*Evidence based reviews and related medical analysis activities for Secretary's Discretionary Advisory Committee on Heritable Disorders in Newborns and Children (DACHDNC)*

HRSA/MCHB

Lisa Prosser, Site PI

09/2016-02/2018. \$26,521

*R01 DK109995-04: Population health impact of a self-insured employer's policy change to cover weight reduction and diabetes prevention interventions for employees, dependents, and retirees with prediabetes*

NIH

Co-I with Effort (Principal Investigator: William H Herman)

07/2016-04/2020. \$2,016,805

*Cost Effectiveness Modeling of a New Shingles Vaccine*

CDC

Lisa Prosser, PI

07/2016-10/2017. \$150,000

*HRSA IDIQ to Support the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC)*

HRSA/MCHB

Lisa Prosser, Site PI

09/2015-03/2017. \$42,743

*Joint Initiative in Vaccine Economics, Phase 5*

CDC

Co-I with Effort (Principal Investigator: David W Hutton)

09/2015-08/2018. \$899,336

*F30 DK105749-03: PA-14-150 F30 Grant*

NIH

Co-I without Effort (Principal Investigator: Anup Das)

05/2015-04/2018. \$115,408

*200-2014-60911: PPHF 2014-Immunization: The Total Burden of Herpes Zoster and Pain in the U.S. and the Portion that can be Prevented with Herpes Zoster Vaccine*

Centers for Disease Control and Prevention

Lisa Prosser, PI

09/2014-08/2016. \$150,000

*DACHDNC Condition Review Group*

HRSA/MCHB

Co-I with Effort (Principal Investigator: Alex Kemper)

07/2014-12/2015. \$79,020

*Evidence-based Reviews for the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children (DACHDNC)*

HRSA/MCHB

Lisa Prosser, Site PI

06/2014-05/2019. \$493,338

*DACHDNC Condition Review Workgroup*

HRSA/MCHB

Lisa, Site PI

1/2013-05/2014. \$51,921

*Improving Patient Decisions About Bariatric Surgery*

PCORI

Co-I with Effort (Principal Investigator: Amir Abbas Ghaferi)

09/2013-08/2016. \$1,528,671

*U22 MC24100-04: SACHDNC Newborn Screening Condition Review Workgroup*

HRSA-DHHS-US through a consortium with ACMG Foundation

Lisa Prosser, Site PI

09/2012-05/2013. \$19,261

*K23 HD070913-05: Brief ED Intervention to Increase Size-Appropriate Child Passenger Restraint Use*  
NIH  
Co-I without Effort (Principal Investigator: Michelle Lea Macy)  
02/2012-01/2017. \$669,600

*Equipping PRISM for Pandemic Influenza (Medical Countermeasures Initiative)*  
FDA-DHHS-US through a consortium with Harvard Pilgrim Health Care  
Lisa Prosser, Site PI  
11/2011-09/2013. \$20,735

*R01 HS020644: Health and Economic Outcomes for Newborn Screening*  
AHRQ  
Lisa Prosser, PI  
09/2011-09/2016. \$2,450,154

*P30 DK092926-05: Michigan Center for Diabetes Translational Research*  
NIH  
Co-I with Effort (Principal Investigator: William H Herman)  
09/2011-08/2016. \$2,519,426

*R01 HD068138: Disorders of Sex Development: Platform for Basic and Translational Research*  
NIH-DHHS-US through a consortium with University of California Los Angeles  
Co-I with Effort (Principal Investigator: David Sandberg)  
09/2011-06/2016. \$1,409,413

*1754.II: Parents' Priorities for Enhanced Access to the Pediatric Medical Home*  
BCBSF  
Co-I (Principal Investigator: Joseph Zickafoose)  
09/2011-09/2012. \$59,005

*Evidence Review Group*  
HRSA-DHHS-US through a consortium with Altarum Institute  
Lisa Prosser, Site PI  
08/2011-08/2012. \$13,746

*U18 HS020516: The Quality Measurement, Evaluation, Testing, Review and Implementation Consortium (Q-METRIC)*  
AHRQ  
Co-I with Effort (Principal Investigator: Gary L Freed)  
03/2011-02/2016. \$7,900,801

*Measuring Preferences for Quality of Life for Child Maltreatment*  
CDC through a consortium with RTI International  
Lisa Prosser, Site PI  
09/2010-07/2012. \$26,619

*001901: Public Values for Pandemic H1N1 Vaccination-Related Adverse Events*  
Centers for Disease Control and Prevention  
Co-I with Effort (Principal Investigator: Marc Zimmerman)  
09/2009-09/2014. \$147,699

*R01 NR011880: HRQOL Impacts of Illness on Family and Caregivers*  
NIH-DHHS-US through a consortium with Harvard University  
Lisa Prosser, Site PI  
09/2009-07/2013. \$554,078

*U01 IP000316: TIME: Technology for Immunization Message Enhancement*  
Centers for Disease Control and Prevention  
Co-I with Effort (Principal Investigator: Kevin Dombkowski)  
09/2009-08/2012. \$548,770

*R01 HD050966-05-S1: Improving Primary Care to Prevent Childhood Obesity (Administrative Supplement)*  
NIH-DHHS-US through a consortium with Harvard Pilgrim Health Care  
Lisa Prosser, Site PI  
09/2009-09/2010. \$11,046

*Cost-effectiveness of Novel H1N1 Influenza Vaccination in the United States*  
Centers for Disease Control and Prevention  
Lisa Prosser, PI  
07/2009-09/2010. \$158,650

*Improving Primary Care to Prevent Childhood Obesity (High Five for Kids)*  
NIH-DHHS-US through a consortium with Harvard Pilgrim Health Care  
Lisa Prosser, Site PI  
07/2009-06/2010. \$34,776

*U01 IP000143: Joint Initiative for Vaccine Economics III [JIVE III]*  
Centers for Disease Control and Prevention through a consortium with Harvard Pilgrim Health Care  
Lisa Prosser, PI  
10/2008-09/2011. \$226,755

*Measuring Preferences for Quality of Life for Child Maltreatment Outcomes*  
Centers for Disease Control and Prevention  
Co-I with Effort (Principal Investigator: Derek Brown)  
01/2008-01/2012. \$400,000

*Cost-effectiveness of Live Attenuated Influenza Vaccine for Children*  
Centers for Disease Control and Prevention  
Lisa Prosser, PI  
01/2007-01/2008. \$89,381

*DACP Grant Program: Economic Barriers to Obesity Prevention and Management in Children*  
Harvard Pilgrim Health Care Foundation  
Lisa Prosser, PI  
01/2006-01/2007. \$50,669

*Combining Clinical Effectiveness and Cost Effectiveness*  
Blue Shield Foundation  
Co-I with Effort (Principal Investigator: Stephen Pearson)  
01/2006-01/2007. \$430,000

*Child Maltreatment Quality of Life Measurement Tool*

Centers for Disease Control and Prevention

Lisa Prosser, PI

09/2005-09/2006. \$65,004

*R01 HD050966: Improving Primary Care to Prevent Childhood Obesity*

National Institute of Child Health and Human Development

Co-I with Effort (Principal Investigator: Matthew Gillman)

01/2005-01/2010. \$3,102,108

*Valuing Children's Health: A Review of Cost-effectiveness Analysis for Pediatric Health Interventions*

Harvard Pilgrim Health Care, DACP Faculty Grant Program

Lisa Prosser, PI

01/2005-12/2006. \$27,754

*R21 LM008707: Methods for Evaluating Bioterrorism Surveillance Systems*

National Library of Medicine

Co-I with Effort (Principal Investigator: Ken Kleinman)

01/2005-01/2006. \$419,430

*U01 P000029: Joint Initiative in Vaccine Economics II*

Centers for Disease Control and Prevention

Co-I with Effort (Principal Investigator: Tracy Lieu)

09/2004-09/2007. \$1,428,261

*K01 DP000089: Health Values and Treatment of Type 2 Diabetes (K-award, Erinn Rhodes)*

Centers for Disease Control and Prevention

Co-I without Effort (Principal Investigator: Erinn Rhodes)

01/2004-01/2007

*R01 HG002085: Expanded Newborn Screening for Metabolic Disorders (R01)*

ELSI/National Human Genome Research Institute

Co-I with Effort (Principal Investigator: Susan Waisbren)

03/2003-02/2006. \$1,766,844

*R01 DC005834: Decision Analysis of Otitis Media Vaccination Strategies (R01)*

National Institute on Deafness and Other Communication Disorders

Co-I with Effort (Principal Investigator: Tracy Lieu)

01/2003-01/2006. \$3,102,108

*Are Managed Care Decisions Consistent with Public Preferences?*

PhRMA Foundation

Lisa Prosser, PI

06/2002-05/2003. \$60,000

*U01 P000029: Joint Initiative in Vaccine Economics*

Centers for Disease Control and Prevention

Co-I with Effort (Principal Investigator: Tracy Lieu)

09/2001-08/2004. \$1,294,084

*Economic Analysis of Strategies to Reduce Influenza Morbidity in Children*  
Centers for Disease Control and Prevention (through Vaccine Safety Datalink)  
Co-I with Effort (Principal Investigator: Tracy Lieu)  
07/2001-06/2002. \$82,565

*U01 HS012019: Randomized Controlled Trial to Reduce Prescribing Errors in Hypertension (R01)*  
Agency for Healthcare Research and Quality  
Co-I with Effort (Principal Investigator: Stephen Soumerai)  
01/2001-01/2004. \$568,684

*Cost-effectiveness of Pneumococcal Conjugate Vaccine*  
Centers for Disease Control and Prevention (through Alliance of Community Health Plans)  
Co-I with Effort (Principal Investigator: Tracy Lieu)  
09/2000-08/2002. \$200,000

*Cost-effectiveness of Interferon Beta-1 a, Interferon Beta-1 b and Glatiramer Acetate in Patients with Relapsing-remitting Multiple Sclerosis*  
National MS Society (dissertation fellowship)  
Lisa Prosser (Doctoral student), PI  
07/1997-06/1999. \$30,000

## Honors and Awards

### **International**

- 1998 Lee B. Lusted Student Prize, Society for Medical Decision Making
- 2005 Best General Podium Presentation, International Society for Pharmacoeconomics and Outcomes Research Annual Meeting
- 2015 Award for Research Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
- 2018 John Eisenberg Award for Practical Application of Medical Decision Making Research, Society for Medical Decision Making
- 2023 Distinguished Service Award, Society for Medical Decision Making

### **National**

- 1995-1997 National Library of Medicine Fellowship
- 1997-1999 National Multiple Sclerosis Society Doctoral Dissertation Fellowship
- 1999 National Cholesterol Outcomes Research Excellence (CORE) Award, 1st place
- 2020 Cost-Effectiveness Analysis Paper of the Year Award, Tufts Center for the Evaluation of Health and Risk
- 2021-2022 Executive Leadership in Academic Medicine (ELAM), Drexel University, PA
- 2025 Child Health Services Research Outstanding Mentor Award, AcademyHealth Annual Research Meeting

### **Institutional**

- 1984-1988 Cornell Tradition Fellowship, Miller Scholarship in Mathematics, Newton North High School Music Department Scholarship, Sons of Italy Scholarship, National Merit Scholarship Semifinalist
- 1991 Master's Thesis Travel Grant, MIT Program on the Pharmaceutical Industry

1992	MIT Award in recognition of founding Women in Technology & Policy
1992	William J. Stewart, Jr., Award for Extracurricular Leadership at MIT
1999-2000	Thomas O. Pyle Fellowship, Harvard Pilgrim Health Care and Harvard Medical School
2002	50th Anniversary Scholars in Medicine Award, Harvard Medical School
2017	Impact Accelerator Award for public health impact, Institute for Healthcare Policy and Innovation, University of Michigan
2021-present	Marilyn Fisher Blanch Research Professor of Pediatrics
2021	MICHR Distinguished Clinical and Translational Research Mentor Award
2023	Outstanding Mentorship Award, Department of Pediatrics Chair's Awards

## Memberships in Professional Societies

1996-present	Member, AcademyHealth Member, Child Health Interest Group Advisory Committee (2016- 2022) Member, Research Insights Advisory Committee (2017- 2022) Member, Planning Committee, Annual Research Meeting (2019)
1996-present	Member, Society for Medical Decision Making Co-Chair, Scientific Review Committee (2008 & 2009 Annual Meetings) Abstract Reviewer. Annual Meetings (2000-2015) Trustee (2010 – 2013) Chair, Publications Committee (2010 – 2013) Chair, Editor-in-Chief Search Committee, Medical Decision Making (2011-2012) Member, Silhouette Journal Committee, Society for Medical Decision Making (2016) Vice President-Elect (2015-2016) Vice President (2016-2017) President-Elect (2018-2019) President (2019-2020) Past President (2020-2021) Nominating Committee (2021-2022)
2000-present	Member, International Health Economics Association Leadership Team, Child Health & Family Wellbeing Interest Group (2020- present)
2001-present	Member, International Society for Pharmacoeconomics and Outcomes Research Co-Chair, Contributed Workshops (2006 Annual International Meeting) Abstract Reviewer, Annual Meetings (2002-2011) Member, Conjoint Analysis Best Practices Task Force (2008 – 2011) Member, Valuing Child Health Task Force (2023-present)
2006-2010	Member, American Society of Health Economists Abstract Reviewer, Annual Meeting (2012)
2012-present	Elected Member, Society for Pediatric Research Co-Lead, Child Population Health Research Task Force (2023-2024)

2014-present Member, Academic Pediatric Association  
2015-present Elected Member, American Pediatric Society

## **Editorial Positions, Boards, and Peer-Review Service**

### **Study Sections**

#### ***International***

2007 Special Reviewer, Canada Foundation for Innovation  
2010 Special Reviewer, European ERANET PRIOMEDCHILD Programme (administered by the Dutch Organization for Health Research and Development)  
2011 Special Reviewer, Medical Research Council (MRC) Grants Pre-Award Peer Review Process, United Kingdom (MRC is the UK equivalent of NIH)  
2015 Special Reviewer, SickKids Foundation New Investigator Program, Toronto, Canada

#### ***National***

2004 Special Reviewer, Research Grants Review Committee, National Eye Institute  
2006 Member, Peer Review Advisory Panel, Cost Effectiveness of Treatments in Multiple Sclerosis (COSTRIMS) Study  
2006 Special Reviewer, Research Grants Review Committee, Decision, Risk and Management Sciences Program, National Science Foundation  
2008 Reviewer, Special Emphasis Panel, Centers for Disease Control and Prevention  
2009 Reviewer, Special Emphasis Panel, Agency for Healthcare Research and Quality  
2010 Member, Objective Review Committee, Maternal and Child Health Bureau and Health Resources and Services Administration's Division of Independent Review (Ad Hoc)  
2012 Reviewer, Special Emphasis Panel, National Institute of Child Health and Human Development  
2015-2016 Reviewer, Concordance Study Section, Agency for Healthcare Research and Quality  
2015-2019 Member, Healthcare Effectiveness and Outcomes Research (HEOR) Study Section, Agency for Healthcare Research and Quality

#### ***Regional***

2007 Member, Research Grants Review Committee, State of Pennsylvania Department of Health

#### ***Editorial Boards***

2008-present Editorial Board, PharmacoEconomics  
2011-2012 Guest Editor, Special Issue on Child Health, PharmacoEconomics  
2017-2019 Guest Editor, Special Issue on Family Spillover Effects, PharmacoEconomics  
2019-present Editorial Board, Value in Health

#### ***Journal Reviewer***

1997-present Journal of Health Economics  
1999 Evaluation and Program Planning  
1999 Medical Care  
2000 American Journal of Managed Care  
2000 Annals of Internal Medicine

2001-present	Medical Decision Making
2001	Future Drugs
2001-present	Pharmacoeconomics
2003-present	Value in Health
2003	Clinical Therapeutics
2004-present	Vaccine
2004	American Journal of Managed Care
2004	Expert Review of Pharmacoeconomics and Outcomes Research
2004-present	Pediatrics
2005-present	The Lancet
2005	Archives of Adolescent Medicine
2005	Epidemiologic Reviews
2005	Journal of Pediatrics
2006-present	Health Affairs
2006	AHRQ
2006	Arch Dermatology
2006	Human Vaccines
2007-present	New England Journal of Medicine
2007	Health Policy
2008-present	Quality of Life Research
2009-present	JAMA
2012	Annual Meeting, American Society of Health Economists
2013	The Patient
2014	Academic Pediatrics
2021	JAMA Health Forum

## Teaching

### *Doctoral Students*

2002-2008	Eileen Sandberg, BA, MS, Harvard University
2004-2005	Tom Concannon, BA, MS, Harvard University
2005-2007	Joseph Ladapo, BA, MPP, Harvard University
2006-2012	Tara Lavelle, BA, MS, Harvard University
2007-2009	Kendrin Sonnevile, MS, RD, LDN, Harvard University
2007-2010	April Kimmel, BA, MS, Harvard University
2007-2012	Davene Wright, BA, Harvard University
2010-2011	Peggy McLaughlin, RN, MS, University of Michigan
2010-2012	Justin Gatwood, MS, University of Michigan
2011-2012	Jongwha Chang, BS, MPH, MS, University of Michigan
2011-2013	Brian Davis, BA, MPH, University of Michigan

2012-2017	Michael Harvey, MPH, University of Michigan
2012-2017	Anup Das, BS, University of Michigan
2014-2018	John Richardson, BA, MPH, University of Michigan
2015-2022	Huey-Fen Chen, BS, MS, University of Michigan
2016-2018	Michael Rozier, BA, MPH, University of Michigan
2016-2022	Tran Doan, BA, MS, University of Michigan
2017-2019	Donald Richardson, BS University of Michigan
2017-2022	Anton Avancena, BS, MPH, University of Michigan
2017-2023	Ellen Kim Deluca, BS, MPH, University of Michigan
2019-2021	Adam Van Deusen, BS, University of Michigan
2019-2022	Grace Chung, MPH, University of Michigan
2021-2025	Christopher Cadham, MPH, University of Michigan
2021-2025	Janamarie Perroud, MPH, University of Michigan
2024-present	Roopa Darwar, MPH, University of Michigan
2024-present	Claire Mellott, BS, University of Michigan
2025-present	Neeti Kulkarni, BA, University of Michigan

### ***Postdoctoral Fellows***

2002-2003	Ruchi Gupta, BS, MD, Harvard University
2007-2009	Kerry McBrien, MD, MPH, Harvard University
2008-2009	Ellen Lipstein, MD, MPH, Massachusetts General Hospital
2009	Heather Van Mater, MD, University of Michigan
2009-2011	Jae Song, MD, University of Michigan
2009-2011	Brian Bennyworth, MD, University of Michigan
2011-2013	Joseph Zickafoose, MD, MPH, University of Michigan
2011-2013	Erica Sears, MD, University of Michigan
2012-2013	Tara Lavelle, PhD, University of Michigan
2012-2013	Adam Sharp, MD, University of Michigan
2014-2015	Sandra Garcia, PhD, University of Michigan
2017-2019	Abram Wagner, PhD, University of Michigan
2019-2021	Joseph Kohne, MD, University of Michigan
2020-2021	Xin Wen, PhD, University of Michigan
2020-2022	Cara Janusz, PhD, University of Michigan
2021-2023	Caroline Hogan, MD, MS, University of Michigan

### **Teaching Activity**

#### ***International***

2012	Lead Instructor: Comparative Effectiveness, Decision Sciences, and Child Health (3-hour workshop), Pediatric Academic Societies Annual Meeting
------	--

- 2013 Lead Instructor: Comparative Effectiveness, Decision Sciences, and Child Health (3-hour workshop), Pediatric Academic Societies Annual Meeting
- 2014 Co-Instructor: Comparative Effectiveness, Decision Sciences, and Child Health (3-hour workshop), Pediatric Academic Societies Annual Meeting
- 2024 Co-Instructor: Getting What You Want: A workshop on career negotiation for health decision scientists across the career lifespan, Society for Medical Decision Making Annual Meeting (2-hour workshop)

***Institutional***

- 1996 Teaching Assistant: Decision Analysis in Clinical Research, Harvard School of Public Health
- 1996 Teaching Assistant: Decision Analysis for Health and Medical Practices, Harvard School of Public Health
- 1996-1998 Teaching Assistant: Management Science, Harvard School of Public Health
- 1997 Teaching Assistant: Decision Theory, Harvard School of Public Health
- 2003-2005 Lecturer and Core Course Faculty: Cost-effectiveness Analysis for Medical Technologies and Pharmaceuticals (summer executive course), Harvard School of Public Health
- 2003-2005 Guest Lecturer: Methods for Decision Analysis in Public Health and Medicine, Harvard, School of Public Health
- 2004-2007 Guest Lecturer: Cost-Effectiveness and Cost-Benefit Analysis for Health Program Evaluation, Harvard School of Public Health
- 2006 Primary Instructor: Decision Analysis Methods in Public Health and Medicine, Harvard School of Public Health
- 2009 Lecturer: Pediatric Health Services Research Fellowship Methods Seminar, University of Michigan, Child Health Evaluation and Research Unit
- 2009-2015 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610), University of Michigan School of Public Health
- 2010 Guest Lecturer: Health Care Markets and Public Policies (BE 608), University of Michigan, Ross School of Business
- 2010 Guest Lecturer: Social and Administrative Sciences Seminar (SOCADMIN 839), University of Michigan, College of Pharmacy
- 2010-2012 Guest Lecturer: Research on Health Care Delivery, Financing & Policy (HHCR 740), Robert Wood Johnson Clinical Scholars Program, University of Michigan, School of Medicine
- 2011 Co-Instructor: Doctoral Seminar in Health Services and Systems Research II (HMP 804), University of Michigan, School of Public Health
- 2011 Guest Lecturer: Pharmacy Health Care Outcomes (PHAR 540), University of Michigan, College of Pharmacy
- 2012-2014 Guest Lecturer: Pharmacy Health Care Outcomes (PHAR 522), University of Michigan, College of Pharmacy
- 2013 Co-Instructor: Economics of Health Management & Policy (HMP 663), University of Michigan, School of Public Health
- 2013-present Co-Instructor: Doctoral Seminar in Health Services and Systems Research II (HMP 806), University of Michigan School of Public Health
- 2014 Co-Instructor: Advanced Topics in Decision Sciences (HMP 680), University of Michigan, School of Public Health

- 2015 Co-Instructor: Doctoral Seminar in Health Services and Systems Research II (HMP 806) University of Michigan School of Public Health 8 students, 2 sessions, 1 final paper
- 2015 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610) University of Michigan School of Public Health 30 students, 1 lecture, 4 hours
- 2016 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610) University of Michigan School of Public Health 30 students, 1 lecture, 4 hours
- 2016 Co-Instructor: Doctoral Seminar in Health Services and Systems Research II (HMP 806), 1 credit course University of Michigan School of Public Health 6 students, 3 sessions, 1 final paper
- 2017 Co-Instructor: Doctoral Seminar in Health Services and Systems Research II (HMP 803), 1 credit course University of Michigan School of Public Health 7 students, 3 sessions, 1 final paper
- 2018 Guest Instructor: Public Health Systems: Achievements and Challenges (PUBHLTH 281), 1 credit course (undergraduates) University of Michigan School of Public Health 50 students, 1 session
- 2019 Lead Instructor: Advanced Topics in Decision Sciences and Cost-effectiveness Analysis (HMP 680) University of Michigan School of Public Health 5 students, 2 credits.
- 2019 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610) University of Michigan School of Public Health 30 students, 1 lecture, 4 hours
- 2019 Guest Lecturer: Ethical, Legal & Social Issues in Genomics & Health (HBEHED 710) University of Michigan School of Public Health 8 students, 1 session
- 2019 Co-Instructor: Doctoral Seminar in Health Services and Systems Research II (HMP 805), 1 credit course University of Michigan School of Public Health 8 students, 3 sessions, 1 final paper
- 2020 Co-Instructor: Doctoral Seminar in Health Services and Systems Research II (HMP 805), 1 credit course University of Michigan School of Public Health 8 students, 3 sessions, 1 final paper
- 2020 Guest Lecturer: Ethical, Legal & Social Issues in Genomics & Health (HBEHED 710) University of Michigan School of Public Health 8 students, 1 session
- 2020 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610) University of Michigan School of Public Health 25 students, 1 lecture, 4 hours
- 2021 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610) University of Michigan School of Public Health 25 students, 1 lecture, 4 hours
- 2021 Guest Lecturer: Ethical, Legal & Social Issues in Genomics & Health (HBEHED 710) University of Michigan School of Public Health 8 students, 1 session
- 2021 Co-Instructor: Doctoral Seminar in Health Services and Systems Research II (HMP 805), 1 credit course University of Michigan School of Public Health 5 students, 3 sessions, 1 final paper
- 2022 Lead Instructor: Advanced Topics in Decision Sciences and Cost-effectiveness Analysis (HMP 680) University of Michigan School of Public Health 4 students, 2 credits
- 2022 Co-Instructor: Doctoral Seminar in Health Services and Systems Research II (HMP 805), 1 credit course University of Michigan School of Public Health 4 students, 3 sessions, 1 final paper

- 2023 Co-Instructor: Doctoral Seminar in Health Services and Systems Research II (HMP 804), 1 credit course University of Michigan School of Public Health 6 students, 3 sessions, 1 final paper
- 2023 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610) University of Michigan School of Public Health 25 students, 1 lecture, 4 hours
- 2024 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610) University of Michigan School of Public Health 25 students, 1 lecture, 4 hours
- 2025 Primary Instructor: Doctoral Seminar in Health Services and Systems Research II (HMP 805), 1 credit course University of Michigan School of Public Health 6 students, 3 sessions, 1 final paper
- 2025 Lead Instructor: Advanced Topics in Decision Sciences and Cost-effectiveness Analysis (HMP 815) University of Michigan School of Public Health 4 students, 2 credits

***Dissertation Committees***

- 2002-2008 Eileen Sandberg, Quality of life of children ages 7-10 with ADHD and the cost-effectiveness of treating ADHD in these children, Harvard University, PhD Program in Health Policy, Committee Member
- 2007-2010 April Kimmel, Decision maker priorities for initiating anti-retroviral treatments, Harvard University, PhD Program in health policy, Committee Member
- 2009-2012 Davene Wright, A review and critique of methods for measuring temporary health states in cost-utility analyses, Harvard University, PhD Program in Health Policy, Co-Chair
- 2009-2012 Tara Lavelle, The impact of pediatric adverse events on the cost-effectiveness of oseltamivir, Harvard University, PhD Program in Health Policy, Co-Chair
- 2011-2012 Jongwha Chang, Essays on physician incentives and pharmaceutical outcomes in asthmatic children, University of Michigan, PhD Program in Health Policy, Committee Member
- 2011-2013 Brian Davis, Topics relating to influenza illness outcomes and costs, University of Michigan, PhD Program in Health Policy, Committee Member
- 2014-2017 Anup Das, Costs and cost-effectiveness of antidepressant treatment for diabetic patients, University of Michigan, PhD Program in Health Policy, Co-Chair
- 2014-2017 Michael Harvey, Cost-effectiveness of high cost, high-risk surgical interventions, University of Michigan, PhD Program in Health Policy, Chair
- 2016-2018 John Richardson, Role of economic evidence in vaccine decision making, University of Michigan, PhD Program in Health Policy, Committee Member
- 2016-2018 Michael Rozier, Health Services Organization and Policy, School of Public Health University of Michigan, University of Michigan, PhD Program in Health Policy, Committee Member
- 2017-2019 Donald Richardson, Industrial and Operations Engineering (PhD Program), College of Engineering, University of Michigan, PhD Program in Health Policy, Committee Member
- 2017-2022 Huey-Fen Chen, Health Services Organization and Policy, University of Michigan, PhD Program in Health Policy, Chair
- 2019-2021 Adam Van Deusen, Industrial and Operations Engineering, University of Michigan, PhD Program in Health Policy, Committee Member
- 2019-2022 Anton Avanceña, Health Services Organization and Policy, University of Michigan, PhD Program in Health Policy, Committee Member
- 2019-2022 Grace Chung, Health Services Organization and Policy, University of Michigan, PhD Program in Health Policy, Committee Member

2019-2022	Tran Doan, Health Services Organization and Policy (PhD Program), School of Public Health, University of Michigan, PhD Program in Health Policy, Chair
2019-2023	Ellen Kim Deluca, Health Services Organization and Policy (PhD Program), School of Public Health, University of Michigan, PhD Program in Health Policy, Chair
2022-2025	Christopher Cadham, Health Services Organization and Policy (PhD Program), School of Public Health, University of Michigan, PhD Program in Health Policy, Chair
2022-2025	Janamarie Perroud, Health Services Organization and Policy (PhD Program), School of Public Health, University of Michigan, PhD Program in Health Policy, Committee Member
2024-present	Roopa Darwar, Health Services Organization and Policy (PhD Program), School of Public Health, University of Michigan, PhD Program in Health Policy, Chair
2024-present	Claire Mellott, Health Services Organization and Policy (PhD Program), School of Public Health, University of Michigan, PhD Program in Health Policy, Committee Member
2025-present	Neeti Kulkarni, Health Services Organization and Policy (PhD Program), School of Public Health, University of Michigan, PhD Program in Health Policy, Committee Member

## **Committee and Administrative Service**

### **Committee Service**

#### ***International***

2006	Contributed Workshops (2006 Annual International Meeting), International Society for Pharmacoeconomics and Outcomes Research, Co-Chair
2013	Expert Panel Member, Value of Vaccines Meeting, Organized by the GAVI Alliance, January 14-15, 2013, Menthon-St-Bernard, France, Expert Panel Member
2013	Value of Vaccines Meeting, Organized by the GAVI Alliance, Menton-St-Bernard, France, Expert Panel Member
2018-2023	Member, Economic Guidelines Task Group, National Advisory Committee on Immunizations (NACI), Office of the Assistant Deputy Minister of Infectious Disease Prevention and Control, Canada
2020-present	Member, Scientific Advisory Committee, The QUOKKA Project - Quality of Life in Kids: Key evidence to strengthen decisions in Australia, University of Melbourne
2020	Symposium Co-Chair and Moderator, Decision Modeling for COVID-19, Society for Medical Decision Making Annual Meeting, Keynote Symposium, Virtual
2021	Symposium Co-Chair and Moderator, COVID-19 Decision Models: Connecting modelers and decision makers, Society for Medical Decision Making Special Event
2022-2023	Spillovers in Health Economic Evaluation and Research (SHEER) Taskforce, Member
2022-2025	ISPOR Pediatric Utilities Task Force, Member and Section Lead

#### ***National***

2005-2007	Institute for Clinical and Economic Review, Harvard Medical School and Harvard Pilgrim Health Care, Lead Decision Scientist
2005-2009	Database Advisory Panel, National Multiple Sclerosis Society, Member
2005	Co-Lead, Advisory Committee on Immunization Practices (ACIP) Influenza Working Group, Economic Subgroup to Review Economic Evidence for Prioritizing Target Groups in Vaccine Shortage Years, Center for Disease Control and Prevention, Co-Lead

2005 New Vaccines for Adolescents: National Stakeholders Meeting, Centers for Disease Control and Prevention/National Vaccine Advisory Committee, Member

2006 Fellowship Standards Task Force, International Society for Pharmacoeconomics and Outcomes Research, Member

2006 Modeling Review Committee, Project MOVE-Measurement of the Value of Exercise, Centers for Disease Control and Prevention, Participant

2007-present Evidence Review Group, Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), Health Resources and Services Administration, Member/Decision Analyst Task Leader

2007 Canada Foundation for Innovation, Special Reviewer

2008-2009 Scientific Review Committee (2008-2009 Annual Meetings), Society for Medical Decision Making, Co-Chair

2008 Advisory Committee on Immunization Practices (ACIP) Influenza Working Group, Economic Subgroup to Review Economic Evidence for Vaccinating Healthy Working-Age Adults, Centers for Disease Control and Prevention, Lead

2009 Special Emphasis Panel, Agency for Healthcare Research and Quality, Reviewer

2009-2011 Evidence Review Group, Institute for Clinical and Economic Review, Member

2010-2013 Publications Committee, Society for Medical Decision Making, Chair

2010-2013 Society for Medical Decision Making, Trustee

2011-2012 Editor-in-Chief Search Committee, Society for Medical Decision Making, Chair

2011-2020 Shingles Work Group, Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention, Member

2011 Evidence Evaluation Methods Working Group, Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), Health Resources and Services Administration, Member

2012 Expert Advisory Panel-Conditions Review Process, Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), Health Resources and Services Administration, Member

2012 NIH Consensus Development Conference: Diagnosing Gestational Diabetes Mellitus, Panel Member

2013-2017 2nd Panel on Cost-Effectiveness in Health and Medicine, Panel Member

2015-2019 Cost Analysis Work Group, Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), Health Resources and Services Administration, Co-lead

2018-2019 Committee to Update Advisory Committee on Immunization Practices (ACIP) Guidance for Economic Studies, Centers for Disease Control and Prevention, Member

2018-2020 Research Insights Project Advisory Committee, AcademyHealth, Member

2019 Expert Advisory Panel for the Review of Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) Review Process, ACHDNC, HRSA, Member

2019 Expert Forum on Improving the Use of Quality of Life Evaluations for Recommendations on Clinical Preventive Services for Children, U.S. Preventive Services Task Force, Member

2022-2025 IVI Scientific Advisory Board, Innovation and Value Initiative, Member

2022-present Value Ethics Working Group, Center for ELSI Resources and Analysis, Member

2024-present Community Preventive Services Task Force, Centers for Disease Control and Prevention, Member

2024	CISNET Consortium External Review Committee, NIH, Member
<b>Regional</b>	
2007	Research Grants Review Committee, State of Pennsylvania Department of Health, Member
<b>Institutional</b>	
2002-2005	Subcommittee on Faculty Parental Leave Policy, Harvard Medical School, Chair
2002-2006	Joint Committee on the Status of Women, Harvard Medical School, Member
2006-2009	Committee on Higher Degrees in Health Policy, Harvard University, Member
2007	Faculty Search Committee, Department of Ambulatory Care and Prevention, Harvard Medical School, Member
2007-2008	Evidence Review Group, Institute for Clinical and Economic Review, Massachusetts General Hospital, Member
2009-2010	Pediatric Psychosocial Services Committee, Department of Pediatrics, University of Michigan Health System, Member
2010-2013	Senior Investigator Advisory Group, Child Health Evaluation and Research Unit, University of Michigan, Member
2010-2022	ADVANCE Advisory Group, University of Michigan Medical School, Member
2010-present	Faculty Development Advisory Committee, University of Michigan Medical School, Member
2011-2015	Mentor Committee, University of Michigan Medical School, Member
2012-2014	Research Advisory Committee, University of Michigan, Department of Pediatrics and Communicable Diseases, Member
2012-present	Health Organization Services Organizations and Policy Doctoral Program Committee, University of Michigan School of Public Health, Member
2013-2023	CHEAR Leadership Team, Child Health Evaluation and Research Center, University of Michigan, Chair
2014-2015	Planning Committee, Faculty Development Symposium, University of Michigan Medical School, Member
2014-2019	Institute for Healthcare Policy and Innovation (IHPI) Education and Training Workshop, University of Michigan, Member
2014-present	Women in Academic Medicine Leadership Committee, University of Michigan Medical School, Member
2015-2016	Faculty Search Committee, University of Michigan School of Dentistry, Member
2015-2019	Advancing Women and Inclusive Leadership Subcommittee, Leadership Development Advisory Group, University of Michigan Medical School, Member
2015-2023	Leadership Development Advisory Group, University of Michigan Medical School, Member
2016-2022	Institute for Healthcare Policy and Innovation (IHPI) Leadership Team, University of Michigan, Member
2016-2023	Faculty Search Committee, Child Health Evaluation and Research Center, Chair
2017	ADVANCE University Advisory Committee, Office of the Provost, Member
2017-2018	Health System Science Curriculum Work Group, Medical School, Member
2017-2018	Parental Leave Advisory Committee, Office of the Provost, Member
2018-2019	IHPI Early Career Faculty Council, Senior Faculty Advisor

2019-2020	Pediatrics Chair Advisory Search Committee, Member
2019-2023	Advancing Inclusive Leadership Committee, University of Michigan Medical School, Co-Chair (2019-2021), Member (2021-2023)
2019-2021	Michigan Medicine Leadership Development Advisory Group, Member
2019-2021	Steering Committee for the Research Initiative on Firearm Injury Prevention, Member
2020-2021	COVID-19 Vaccine & Therapeutics Taskforce Vaccine Safety/Efficacy Team, Member
2021	Committee to Review Research Professor Track Criteria, Office of the Provost, Member
2021-2022	Campaign Theme Group – Health and Wellness, Member
2022-2023	Search Committee, Director of Institute for Research on Women and Gender, Office of the Vice President for Research, Chair
2022	Search Committee, Chief Procurement Officer, University of Michigan, Member
2022-2023	Selection Committee, Presidential Awards for Public Impact, Member
2022-present	Selection Committee, Research Track Faculty Awards, Member
2025	Research Scientist Appointment & Promotion Criteria Review Committee, Chair

### ***Consulting Positions***

1988-1990	Systems Consultant, Andersen Consulting (now Accenture), Stamford, CT
1991	Health Policy Analyst, Abt Associates, Cambridge, MA
1992-1995	Health Care Management Consultant, The Wilkerson Group, New York, NY
2008-2010	Visiting Scientist, United Biosource, Ann Arbor, MI

### **Visiting Professorships and Extramural Invited Presentations**

#### ***Visiting Professorships***

01/2008-12/2010	Visiting Scientist, United Biosource, Ann Arbor, MI
10/2013	Visiting Professor, Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto & Child Health Evaluative Sciences (CHES), SickKids Hospital, Toronto, Canada
03/2014	Visiting Professor, Department of Health Policy and Management, Fay W. Boozman College of Public Health, University of Arkansas, Fayetteville, Arkansas
01/2016	Visiting Professor, Center for Child Health, Behavior, and Development, Seattle Children's Hospital, Seattle, Washington
03/2022	Visiting Professor, Center for Healthcare Research in Pediatrics, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA
03/2023	Visiting Professor, Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
01/2026	Visiting Professor, School of Population and Global Health, University of Melbourne, Melbourne, Australia

#### ***Extramural Invited Presentations***

1. Cost-effectiveness of Interferon beta-1a, Interferon beta-1b, and Glatiramer Acetate in Multiple Sclerosis, Society for Medical Decision Making, October 2000, Cincinnati, OH
2. Do Risk Attitudes Differ Across Domains and Respondent Types?, Society for Medical Decision Making, October 2001, San Jose, CA

3. Economic Analysis of Strategies to Reduce Influenza Morbidity in Children, National Immunization Program, Centers for Disease Control and Prevention, January 2003, Atlanta, GA
4. Economic Analysis of Strategies to Reduce Influenza Morbidity in Children, Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention, January 2003, Atlanta, GA
5. An Economic Analysis of Rapid Tests and Antiviral Treatments for Influenza in Children, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2004, Arlington, VA
6. Using Economic Information to Prioritize Subgroups During Influenza Vaccine Shortages, Advisory Committee on Immunization Practices (ACIP) Influenza Working Group, January 2005, Atlanta, GA
7. Costs of Delivering Adult Influenza Vaccination in Non-traditional Settings, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2005, Washington, DC
8. Projected Costs, Risks, and Benefits of Influenza Vaccination of Children, Center for Health Services Research, Henry Ford Health System, January 2006, Detroit, MI
9. Cost-effectiveness of Expanded Newborn Screening, Annual Meeting of the New England Consortium of Metabolic Programs, January 2006, Worcester, MA
10. Cost-effectiveness of Expanded Newborn Screening, New England Consortium of Metabolic Programs, March 2006, Boston, MA
11. Projected Health Benefits, Risks, and Cost-effectiveness of Influenza Vaccination: Children Aged 5-17 Years, Conference on Routine Vaccination Against Influenza for Older Children, Centers for Disease Control and Prevention, January 2007, Atlanta, GA
12. Projected Costs, Risks, and Benefits of Influenza Vaccination of Children, Center for Health Services Research, Henry Ford Health System, March 2007, Detroit, MI
13. Measuring Health Preferences for use in Cost-Utility and Benefit Analyses of Interventions in Children: Theoretical and methodological considerations, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2007, Arlington, VA
14. Cost-effectiveness of Influenza Vaccination: Updated Estimates for Children Aged 2-4 Years, Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention, October 2007, Atlanta, GA
15. Initiative on Medication Management, Policy Analysis, Research & Training (IMPART), Dalhousie University, November 2007, Halifax, Nova Scotia, Canada
16. Projected Health Benefits, Risks, and Cost-effectiveness of Influenza Vaccination, Child Health Evaluation and Research (CHEAR) Unit, Department of Pediatrics, University of Michigan Medical School, January 2008, Ann Arbor, MI
17. Cost-effectiveness of Universal Vaccination, Symposium: Universal Vaccination Against Influenza, National Foundation for Infectious Diseases, Annual Conference on Vaccine Research, May 2008, Baltimore, MD
18. Valuing Health Across the Lifespan, Society for Medical Decision Making, October 2008, Philadelphia, PA
19. Cost-effectiveness of pH1N1 Influenza Vaccination in the United States, Centers for Disease Control and Prevention, January 2009, Atlanta, GA
20. Valuing Health for Children and Adults, Pediatric Academic Societies Annual Meeting, April 2009, Baltimore, MD
21. Eliciting Time-trade off Amounts for Health States in Hypothetical Individuals of Different Ages Using a Discrete Choice Experiment, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2009, Orlando, FL
22. Use of Proxies for Valuing Children's Health, American Society of Health Economists, 3rd Biennial Meeting, June 2010, Cornell University

23. Eliciting Time Trade-off Amounts Using a Discrete Choice Experiment, American Society of Health Economists, 3rd Biennial Meeting, June 2010, Cornell University
24. Trends in Utility Elicitation Methods: Is There Still a Role For Direct Elicitation?, Society of Medical Decision Making, October 2010, Toronto, Ontario, Canada
25. Community-based Value for H1N1 Influenza Illnesses and Vaccination-related Adverse Events, Centers for Disease Control and Prevention, January 2011, Atlanta, GA
26. Finding Utility Measures for Influenza Illness, Eastern Economic Association, February 2011, New York City, New York
27. Cost-effectiveness and Vaccine Policy, Global Vaccines 202x: Access, Equity, Ethics Symposium, May 2011, Philadelphia, PA
28. Evidence Evaluation and Methods Workgroup: Update on Developing a Decision Analysis Tree, Secretary's Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), November 2011, Washington, DC
29. Cost-effectiveness of Influenza Vaccine, National Foundation for Infectious Diseases and the Emory School of Medicine, November 2011, Atlanta, GA
30. Cost-effectiveness of Influenza Vaccination, National Influenza Vaccine Summit, May 2012, Atlanta, GA
31. Measuring Family HRQOL Spillover Effects Using Direct Health Utility Assessment, Society of Medical Decision Making, October 2012, Phoenix, AZ
32. Cost-effectiveness of Influenza Vaccine, National Foundation for Infectious Diseases and the Emory Department of Medicine, November 2012, Miami, FL
33. Cost-effectiveness of Influenza Vaccine, National Foundation for Infectious Diseases and the Emory Department of Medicine, March 2013, Chicago, IL
34. Comparative Effectiveness & Child Health, Toronto Health Economics and Technology Assessment Collaborative (THETA), October 2013, Toronto, Ontario, Canada
35. Comparative Effectiveness & Child Health, Seminar Series on Evidence-Based Medicine, University of Arkansas, March 2014, Little Rock, AK
36. Economic Impacts of Child Health Research, Pediatric Academic Societies, April 2014, Vancouver, British Columbia, Canada
37. Cost-effectiveness Analysis and U.S. Health Policy, 36th Annual Meeting of the Society for Medical Decision Making Symposium: What Should the Role of CEA Be in Health Policy and Medical Decision Making, October 2014, Miami, FL
38. 2nd Panel on Cost-Effectiveness in Health and Medicine: Motives, methods, and key issues, International Health Economics Association, July 2015, Milan, Italy
39. Measuring Family HRQOL Spillover Effects for Newborn Screening Conditions, International Health Economics Association, July 2015, Milan, Italy
40. Newborn Screening for X-linked Adrenoleukodystrophy (X-ALD): Final Report from the Condition Review Workgroup, Discretionary Advisory Committee for Heritable Disorders in Newborns and Children, August 2015, Rockville, MD
41. Newborn Screening Decisions: The Role of Cost-effectiveness Evidence, Michigan Department of Health and Human Services, September 2015, Lansing, MI
42. Council for the Advancement of Nursing Science Annual Meeting Innovative Methods to Accelerate Family Nursing Research, American Academy of Nursing, October 2015, Washington, DC
43. Methods for Measuring How Childhood Illness Affects Parents and Family Members, Agency for Healthcare Research and Quality, October 2015, Arlington, VA

44. Second Panel on Cost-Effectiveness in Health and Medicine, National Academy of Sciences Reporting results of cost-effectiveness analyses, January 2016, Ann Arbor, MI
45. 38th Annual Meeting of the Society for Medical Decision, Making Measuring Patient Preferences for Bariatric Surgery: A Discrete Choice Experiment, October 2016, Vancouver, British Columbia, Canada
46. 38th Annual Meeting of the Society for Medical Decision Making, Panel: Recommendations of the Second Panel on Cost-effectiveness in Health and Medicine, October 2016, Vancouver, British Columbia, Canada
47. Seminar Series, Center for Child Health Behavior and Development, Seattle Children's Hospital Family Effects of Illness, Seattle Children's Hospital, January 2016, Seattle, Washington
48. Children's Vision: A National Workshop, Using Decision Analysis to Inform Newborn Screening Policy, February 2016, Ann Arbor, MI
49. Newborn Screening for Neuromuscular Diseases International Meeting Economic Evaluation, Newborn Screening, and Pompe Disease, March 2016, St. Louis, MO
50. Using Decision Analysis to Inform Newborn Screening Policy, Helen DeVos Children's Hospital, January 2017, Ann Arbor, MI
51. Second Panel on Cost-Effectiveness in Health and Medicine, International Health Economics Association Annual Meeting, International Health Economics Association, January 2017, Boston, MA
52. Orphan Drug Assessment and Pricing Summit, Institute for Clinical and Economic Review, January 2017, Washington, DC
53. Center for Health Decision Science, Economic Evaluation of Vaccination for Prevention of Herpes Zoster and Related Complications, Harvard University, Harvard T.H. Chan School of Public Health, January 2017, Cambridge, MA.
54. Advisory Committee on Immunization Practices (ACIP), Economic evaluation of vaccination for prevention of herpes zoster and related complications, ACIP, October 2017, Atlanta, GA
55. Advisory Committee for Heritable Disorders in Newborns and Children (ACHDNC), Population-level outcomes for newborn screening of spinal muscular atrophy, ACHDNC, February 2018, Rockville, MD
56. Centers for Disease Control and Prevention Joint Initiative in Vaccine Economics, CDC, June 2018, Atlanta, GA
57. Child Health Evaluative Sciences Program, Decision analysis of newborn screening of spinal muscular atrophy, SickKids Hospital, October 2018, Toronto, Canada
58. University of North Carolina at Chapel Hill (UNC) Division of Pharmaceutical Outcomes and Policy Seminar, Use of Cost-effectiveness Analysis in U.S. Immunization Policy, UNC-Virtual, January 2020, Chapel Hill, NC
59. Advisory Committee on Immunization Practices (ACIP), Projected Risks and Health Benefits of Vaccination against Herpes Zoster and Related Complications. February 2021
60. Centers for Disease Control and Prevention, Economic Evaluation for Health Interventions: Integrating Values, Health Economics Research Group Annual Meeting, Keynote Speaker, January 2022
61. Advisory Committee for Heritable Disorders in Newborns and Children (ACHDNC), Population-level outcomes for newborn screening of MPS-II, ACHDNC, February 2022
62. Centers for Disease Control and Prevention, Immunization Services Division Seminar, February 2022
63. Center for Healthcare Research in Pediatrics, Department of Population Medicine, Harvard University, Boston, MA. Using Decision Sciences to Assess the Value of Vaccination Against COVID-19 in Children and Adults, March 2022
64. Health Economics Research Centre, Oxford University, Measuring Health Utilities for COVID-19 Illness: Implications for Valuing Child Health, May 2022, Oxford, United Kingdom

65. Advisory Committee for Heritable Disorders in Newborns and Children (ACHDNC), HRSA, Population-level Outcomes for Newborn Screening of GAMT Deficiency, ACHDNC, May 2022
66. 44th Annual Meeting of the Society for Medical Decision Making, Panel: Striving for a Societal Perspective for Economic Evaluation: How to Capture Wider Benefits, Costs Falling on Different Payers and Account for Impacts on Inequality, October 2022, Seattle, WA
67. Public Health Modeling Unit Seminar Series, Yale School of Public Health, Using Decision Sciences to Assess the Value of Vaccination Against COVID-19 in Children and Adults, April 2023, New Haven, CT.
68. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention, Economic Analysis of Vaccination with mRNA Booster Dose against COVID-19 Among Adults, September 2023, virtual meeting.
69. Center for Healthcare Policy and Research, UC Davis Health, Assessing the Value of Vaccination Against COVID-19 in Children and Adults, January 2024
70. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention, Economic Analysis of an Additional Dose of COVID-19 Vaccine, February 2024
71. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention, Economic Analysis of COVID-19 Vaccination, June 2024
72. Advisory Committee on Immunization Practices (ACIP), Economic Analysis of an Additional Dose of COVID-19 Vaccination, October 2024
73. Symposium: Celebrating Cost-effectiveness Analysis, Tufts Center for Evaluation of Value and Risk in Health Policy Implications and Ideas, Invited Panelist, October 2024
74. Melbourne Health Economics Seminar, The University of Melbourne, Using Decision Sciences to Understand the Value of Vaccination against COVID-19 Illness in Children and Adults, January 2026

#### ***Intramural Invited Presentations***

1. Patient-specific Factors in Clinical Decision-making: The Relationship Between Risk Attitude and Treatment Choice in Patients with Multiple Sclerosis, Harvard Medical School, Department of Ambulatory Care and Prevention, March 2000, Boston, MA
2. Patient Preferences for Treatments and Health States in Multiple Sclerosis, Harvard School of Public Health, Center for Risk Analysis, April 2000, Boston, MA
3. Introduction to Methods for Decision Analysis in Health, University of California, Department of Family and Preventative Medicine, November 2001, San Diego, CA
4. Cost-effectiveness of Cholesterol-lowering Interventions: Challenges of Using CEA in Decision-Making, Harvard Medical School, Department of Ambulatory Care and Prevention/Pharmaceutical Policy Research, January 2002, Boston, MA
5. Preferences for Outcomes Prevented by Pneumococcal Conjugate Vaccine: Challenges in Using Parents as Proxies for Valuing Children's Health States, Dana Farber/Harvard Cancer Center, November 2002, Boston, MA
6. Economic Analysis of Strategies to Reduce Influenza Morbidity in Children, Harvard Medical School, Department of Ambulatory Care and Prevention, January 2003, Boston, MA
7. Are Managed Care Decisions Consistent with Public Preference?, Harvard Medical School, Department of Ambulatory Care and Prevention, January 2004, Boston, MA
8. The Economics of Childhood Vaccination, Harvard Medical School, Department of Ambulatory Care and Prevention, January 2005, Boston, MA

9. Should We Vaccinate More Children Against Influenza? Projected Health Benefits, Risks, and Cost-effectiveness, Harvard School of Public Health, Department of Health Policy and Management, January 2006, Boston, MA
10. Expanded Newborn Screening: The Effect of False Positive Test Results on Quality of Life, Harvard Medical School, Department of Ambulatory Care and Prevention, January 2006, Boston, MA
11. Economic Values for Newborn Screening of Metabolic Disorders and Related Outcomes, Beth Israel Deaconess Medical Center, Harvard Newborn Medicine Epidemiology and Clinical Medicine Conference, January 2006, Boston, MA
12. Initiative on Medication Management, Policy Analysis, Research & Training (IMPART), Dalhousie University, November 2007, Halifax, Nova Scotia, Canada
13. Cost-effectiveness of 2009 Pandemic Influenza A(H1N1) Vaccination in Children and Adults, University of Michigan, Child Health Evaluation and Research (CHEAR) Unit, January 2010, Ann Arbor, MI
14. Cost-effectiveness and Child Health, University of Michigan, Department of Pediatrics, January 2010, Ann Arbor, MI
15. Cost-effectiveness of 2009 Pandemic Influenza A(H1N1) Vaccination in the United States, University of Michigan, School of Pharmacy, January 2010, Ann Arbor, MI
16. Newborn Screening: Cost-effectiveness and Health Policy, University of Michigan, Neonatology Research Conference, January 2011, Ann Arbor, MI
17. Newborn Screening: Cost-effectiveness and Health Policy, University of Michigan, Department of Pediatrics, January 2011, Ann Arbor, MI
18. Comparative Effectiveness and Child Health, University of Michigan, Child Health Evaluation and Research (CHEAR) Unit, January 2011, Ann Arbor, MI
19. Using Decision Analysis to Inform Newborn Screening Policy, University of Michigan, Child Health Evaluation and Research (CHEAR) Unit, January 2013, Ann Arbor, MI
20. Influenza Vaccination post-2009; Projected Health Benefits, Risks, and Cost-effectiveness, University of Michigan, Child Health Evaluation and Research (CHEAR) Unit, January 2013, Ann Arbor, MI
21. Measuring the Spillover Effects of Illness on Parents, Spouses, and Children, University of Michigan, Child Health Evaluation and Research (CHEAR) Unit, January 2014, Ann Arbor, MI
22. Introduction to Conjoint Analysis and Related Methods, University of Michigan, Institute for Healthcare Policy and Innovation (IHPI) Methods Seminar, January 2014, Ann Arbor, MI
23. Academic Mentoring, University of Michigan, Department of Pediatrics and Communicable Diseases, April 2015, Ann Arbor, MI
24. Economic Evaluation and Child Health Policy, University of Michigan Injury Center, May 2015, Ann Arbor, MI
25. Panel on Health Services Research, University of Michigan, School of Public Health, September 2015, Ann Arbor, MI
26. Center for Health Decision Science, Economic Evaluation of Vaccination for Prevention of Herpes Zoster and Related Complications, Harvard University, Harvard T.H. Chan School of Public Health, January 2017, Cambridge, MA
27. Using Decision Analysis for Newborn Screening Policy, Robert Wood Johnson Clinical Scholars Program, University of Michigan, 2016, Ann Arbor, MI
28. Introduction to Conjoint Analysis, Institute for Healthcare Policy and Innovation (IHPI) Methods Seminar, University of Michigan, 2016, Ann Arbor, MI
29. Consideration of Economic Endpoints for Clinical (and observational) Trials, Pediatrics Clinical Research Conference, University of Michigan, 2017, Ann Arbor, MI

30. Consideration of Economic Endpoints for Clinical (and observational) Trials, Woodson Scholars Seminar, Dept of Pediatrics, University of Michigan, 2017, Ann Arbor, MI
31. Using Decision Modeling to Inform Newborn Screening Policy Decisions for Pompe Disease: A Case Study, Center for Healthcare Engineering and Patient Safety, University of Michigan, 2017, Ann Arbor, MI
32. Vaccine Decision Making, mHealthy Advisory Committee, University of Michigan, 2018, Ann Arbor, MI
33. Introduction to Conjoint Analysis, University of Michigan, Susan B. Meister Child Health Evaluation and Research (CHEAR) Center, Methods Seminar, 2019, Ann Arbor, MI
34. Valuing Child Health, University of Michigan, Susan B. Meister Child Health Evaluation and Research (CHEAR) Center, 2019, Ann Arbor, MI
35. COVID-19 and Child Health, University of Michigan, School of Public Health Symposium, 2020, Ann Arbor, MI
36. Cost-Effectiveness of Vaccination to Prevent COVID-19 Illness. MIDAS Symposium - Computing Our Way Out of a Pandemic: Modeling in the Face of COVID-19, University of Michigan, 2021, Ann Arbor, MI
37. Using Decision Sciences to Assess the Value of COVID-19 Vaccination in Children and Adults. HMP Research Seminar, University of Michigan, School of Public Health, 2022, Ann Arbor, MI
38. Mitigating COVID-19 Impact on Research, Internal Medicine Research Symposium, University of Michigan, 2022, Ann Arbor, MI
39. Introduction to Conjoint Analysis, University of Michigan, Susan B. Meister Child Health Evaluation and Research (CHEAR) Center Seminar Series, Methods Seminar, 2023, Ann Arbor, MI
40. Cost-effectiveness of Risk-Based Prevention for Dental Caries. Oral Health Sciences Research Seminar Series, School of Dentistry, University of Michigan, 2023, Ann Arbor, MI
41. Assessing the Value of Prevention Programs Using Decision Science. School of Dentistry Research Retreat, School of Dentistry, University of Michigan, 2024, Ann Arbor, MI
42. Introduction to Cost-effectiveness Analysis, University of Michigan, Susan B. Meister Child Health Evaluation and Research (CHEAR) Center Seminar Series, Methods Seminar, 2024, Ann Arbor, MI
43. Getting What You Want: An introduction to negotiation principles for the academic job market. HSOP Doctoral Student Seminar Series, School of Public Health, University of Michigan, 2025, Ann Arbor, MI.
44. Infection Associated Chronic Conditions Case Competition Symposium, Invited Expert Panelist. Ross Business School, University of Michigan, October 2025.

## Bibliography

### *Peer-Reviewed Journals and Publications*

1. **Prosser LA**, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. *Ann Intern Med.* 2000;132(10):769-779. doi:10.7326/0003-4819-132-10-200005160-00002
2. **Prosser LA**, Koplan JP, Neumann PJ, Weinstein MC. Barriers to using cost-effectiveness analysis in managed care decision making. *Am J Manag Care.* 2000;6(2):173-179.
3. **Prosser LA**, Stinnett AA, Goldman L, Weinstein MC. Cost-effectiveness analyses (letter). *Ann Intern Med.* 2001;135(5): 383.
4. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis. *Med Decis Making.* 2002;22(6):506-513. doi:10.1177/0272989X02238299
5. Lieu TA, Thompson KM, **Prosser LA**, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL. Emerging issues in vaccine economics: perspectives from the USA. *Expert Rev Vaccines.* 2002;1(4):433-442. doi:10.1586/14760584.1.4.433

6. Wang SJ, Middleton B, **Prosser LA**, Bardon CG, Spurr CD, Carchidi PJ, Kittler AF, Goldszer RC, Fairchild DG, Sussman AJ, Kuperman GJ, Bates DW. A cost-benefit analysis of electronic medical records in primary care. *Am J Med.* 2003;114(5):397-403. doi:10.1016/s0002-9343(03)00057-3
7. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis. *Mult Scler.* 2003;9(3):311-319. doi:10.1191/1352458503ms903oa
8. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. *Value Health.* 2004;7(5):554-568. doi:10.1111/j.1524-4733.2004.75007.x
9. **Prosser LA**, Ray GT, O'Brien M, Kleinman K, Santoli J, Lieu TA. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. *Pediatrics.* 2004;113(2):283-290. doi:10.1542/peds.113.2.283
10. Simon SR, Majumdar SR, **Prosser LA**, Salem-Schatz S, Warner C, Kleinman K, Miroshnik I, Soumerai SB. Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial. *Am J Med.* 2005;118(5):521-528. doi:10.1016/j.amjmed.2004.12.023
11. **Prosser LA**, Bridges CB, Uyeki TM, Rêgo VH, Ray GT, Meltzer MI, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Values for preventing influenza-related morbidity and vaccine adverse events in children. *Health Qual Life Outcomes.* 2005;3:18. Published 2005 Mar 21. doi:10.1186/1477-7525-3-18
12. **Prosser LA**, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. *Emerg Infect Dis.* 2006;12(10):1548-1558. doi:10.3201/eid1210.051015
13. Gupta RS, Bewtra M, **Prosser LA**, Finkelstein JA. Predictors of hospital charges for children admitted with asthma. *Ambul Pediatr.* 2006;6(1):15-20. doi:10.1016/j.ambp.2005.07.001
14. Wittenberg E, Halpern E, Divi N, **Prosser LA**, Araki SS, Weeks JC. The effect of age, race and gender on preference scores for hypothetical health states. *Qual Life Res.* 2006;15(4):645-653. doi:10.1007/s11136-005-3514-3
15. Skelding PC, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, Prosser L, Simon SR. Clinical and nonclinical correlates of adherence to prescribing guidelines for hypertension in a large managed care organization. *J Clin Hypertens.* 2006;8(6):414-419. doi:10.1111/j.1524-6175.2006.05337.x
16. Simon SR, Rodriguez HP, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, Soumerai SB, **Prosser LA**. Economic analysis of a randomized trial of academic detailing interventions to improve use of antihypertensive medications. *J Clin Hypertens.* 2007;9(1):15-20. doi:10.1111/j.1524-6175.2006.05684.x
17. Eisenberg DM, Post DE, Davis RB, Connelly MT, Legedza AT, Hrbek AL, **Prosser LA**, Buring JE, Inui TS, Cherkin DC. Addition of choice of complementary therapies to usual care for acute low back pain: a randomized controlled trial. *Spine.* 2007;32(2):151-158. doi:10.1097/01.brs.0000252697.07214.65
18. **Prosser LA**, Wittenberg E. Do risk attitudes differ across domains and respondent types?. *Med Decis Making.* 2007;27(3):281-287. doi:10.1177/0272989X07300602
19. **Prosser LA**, Corso PS. Measuring health-related quality of life for child maltreatment: a systematic literature review. *Health Qual Life Outcomes.* 2007;5:42. Published 2007 Jul 16. doi:10.1186/1477-7525-5-42
20. Ladapo JA, Neumann PJ, Keren R, **Prosser LA**. Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the US. *Pharmacoeconomics.* 2007;25(10):817-828. doi:10.2165/00019053-200725100-00002
21. **Prosser LA**, Hammitt JK, Keren R. Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations. *Pharmacoeconomics.* 2007;25(9):713-726. doi:10.2165/00019053-200725090-00001
22. Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, **Prosser LA**.

- Community and patient values for preventing herpes zoster. *Pharmacoeconomics*. 2008;26(3):235-249. doi:10.2165/00019053-200826030-00006
23. **Prosser LA**, O'Brien MA, Molinari NA, Hohman KH, Nichol KL, Messonnier ML, Lieu TA. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. *Pharmacoeconomics*. 2008;26(2):163-178. doi:10.2165/00019053-200826020-00006
  24. Ortega-Sanchez IR, Lee GM, Jacobs RJ, **Prosser LA**, Molinari NA, Zhang X, Baine WB, McCauley MM, Miller T. Projected cost-effectiveness of new vaccines for adolescents in the United States. *Pediatrics*. 2008;121 Suppl 1:S63-S78. doi:10.1542/peds.2007-1115H
  25. **Prosser LA**, Ladapo JA, Rusinak D, Waisbren SE. Parental tolerance of false-positive newborn screening results. *Arch Pediatr Adolesc Med*. 2008;162(9):870-876. doi:10.1001/archpediatrics.2008.1
  26. Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, **Prosser LA**. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster. *Pharmacoeconomics*. 2009;27(12):1005-1016. doi:10.2165/11314000-000000000-00000
  27. O'Brien MA, **Prosser LA**, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, Hinrichsen VL, Mehta J, Colborn DK, Lieu TA. New vaccines against otitis media: projected benefits and cost-effectiveness. *Pediatrics*. 2009;123(6):1452-1463. doi:10.1542/peds.2008-1482
  28. **Prosser LA**. Current challenges and future research in measuring preferences for pediatric health outcomes. *J Pediatr*. 2009;155(1):7-9. doi:10.1016/j.jpeds.2009.03.007
  29. Wright DR, Wittenberg E, Swan JS, Miksad RA, **Prosser LA**. Methods for measuring temporary health States for cost-utility analyses. *Pharmacoeconomics*. 2009;27(9):713-723. doi:10.2165/11317060-000000000-00000
  30. Lipstein EA, Perrin JM, Waisbren SE, **Prosser LA**. Impact of false-positive newborn metabolic screening results on early health care utilization. *Genet Med*. 2009;11(10):716-721. doi:10.1097/GIM.0b013e3181b3a61e
  31. Sonnevile KR, La Pelle N, Taveras EM, Gillman MW, **Prosser LA** Economic and other barriers to adopting recommendations to prevent childhood obesity: results of a focus group study with parents. *BMC Pediatr*. 2009;9:81. Published 2009 Dec 21. doi:10.1186/1471-2431-9-81
  32. Grosse SD, **Prosser LA**, Asakawa K, Feeny D. QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique. *Expert Rev Pharmacoecon Outcomes Res*. 2010;10(3):293-308. doi:10.1586/erp.10.24
  33. Perrin JM, Knapp AA, Browning MF, Comeau AM, Green NS, Lipstein EA, Metterville DR, Prosser L, Queally D, Kemper AR. An evidence development process for newborn screening. *Genet Med*. 2010;12(3):131-134. doi:10.1097/GIM.0b013e3181d28eb1
  34. **Prosser LA**, Kong CY, Rusinak D, Waisbren SL. Projected costs, risks, and benefits of expanded newborn screening for MCADD. *Pediatrics*. 2010;125(2):e286-e294. doi:10.1542/peds.2009-0605
  35. Lipstein EA, Vorono S, Browning MF, Green NS, Kemper AR, Knapp AA, **Prosser LA**, Perrin JM. Systematic evidence review of newborn screening and treatment of severe combined immunodeficiency. *Pediatrics*. 2010;125(5):e1226-e1235. doi:10.1542/peds.2009-1567,
  36. McBrien KA, Kleinman KP, Abrams AM, **Prosser LA**. Use of outcomes to evaluate surveillance systems for bioterrorist attacks. *BMC Med Inform Decis Mak*. 2010;10:25. Published 2010 May 7. doi:10.1186/1472-6947-10-25
  37. **Prosser LA**, Payne K, Rusinak D, Shi P, Uyeki T, Messonnier M. Valuing health across the lifespan: health state preferences for seasonal influenza illnesses in patients of different ages. *Value Health*. 2011;14(1):135-143. doi:10.1016/j.jval.2010.10.026
  38. Bridges JF, Hauber AB, Marshall D, Lloyd A, **Prosser LA**, Regier DA, Johnson FR, Mauskopf J. Conjoint analysis

applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. *Value Health*. 2011;14(4):403-413. doi:10.1016/j.jval.2010.11.013

39. **Prosser LA**, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V, Lieu TA. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years. *Arch Pediatr Adolesc Med*. 2011;165(2):112-118. doi:10.1001/archpediatrics.2010.182
40. Wang YC, Cheung AM, Bibbins-Domingo K, **Prosser LA**, Cook NR, Goldman L, Gillman MW. Effectiveness and cost-effectiveness of blood pressure screening in adolescents in the United States. *J Pediatr*. 2011;158(2):257-64.e647. doi:10.1016/j.jpeds.2010.07.058,
41. Belfort MB, Zupancic JA, Riera KM, Turner JH, **Prosser LA**. Health state preferences associated with weight status in children and adolescents. *BMC Pediatr*. 2011;11:12. Published 2011 Feb 7. doi:10.1186/1471-2431-11-12
42. Eisenberg D, Freed GL, Davis MM, Singer D, **Prosser LA**. Valuing health at different ages: evidence from a nationally representative survey in the US. *Appl Health Econ Health Policy*. 2011;9(3):149-156. doi:10.2165/11587340-000000000-00000
43. Wittenberg E, **Prosser LA**. Ordering errors, objections and invariance in utility survey responses: a framework for understanding who, why and what to do. *Appl Health Econ Health Policy*. 2011;9(4):225-241. doi:10.2165/11590480-000000000-00000
44. Taveras EM, Gortmaker SL, Hohman KH, Horan CM, Kleinman KP, Mitchell K, Price S, **Prosser LA**, Rifas-Shiman SL, Gillman MW. Randomized controlled trial to improve primary care to prevent and manage childhood obesity: the High Five for Kids study. *Arch Pediatr Adolesc Med*. 2011;165(8):714-722. doi:10.1001/archpediatrics.2011.44
45. **Prosser LA**, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, Dunham KM, Meltzer MI. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States. *PLoS One*. 2011;6(7):e22308. doi:10.1371/journal.pone.0022308
46. Rhodes ET, **Prosser LA**, Lieu TA, Songer TJ, Ludwig DS, Laffel LM. Preferences for type 2 diabetes health states among adolescents with or at risk of type 2 diabetes mellitus. *Pediatr Diabetes*. 2011;12(8):724-732. doi:10.1111/j.1399-5448.2011.00772.x
47. Lavelle TA, Meltzer MI, Gebremariam A, Lamarand K, Fiore AE, **Prosser LA**. Community-based values for 2009 pandemic influenza A H1N1 illnesses and vaccination-related adverse events. *PLoS One*. 2011;6(12):e27777. doi:10.1371/journal.pone.0027777
48. **Prosser LA**. Comparative effectiveness and child health. *Pharmacoeconomics*. 2012;30(8):637-645. doi:10.2165/11633830-000000000-00000
49. Lavelle TA, Uyeki TM, **Prosser LA**. Cost-effectiveness of oseltamivir treatment for children with uncomplicated seasonal influenza. *J Pediatr*. 2012;160(1):67-73.e6. doi:10.1016/j.jpeds.2011.07.001
50. Gatwood J, Meltzer MI, Messonnier M, Ortega-Sanchez IR, Balkrishnan R, **Prosser LA**. Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations. *Drugs*. 2012;72(1):35-48. doi:10.2165/11597310-000000000-00000
51. **Prosser LA**, Grosse SD, Kemper AR, Tarini BA, Perrin JM. Decision analysis, economic evaluation, and newborn screening: challenges and opportunities. *Genet Med*. 2013;14(8):703-712. doi:10.1038/gim.2012.24
52. **Prosser LA**, Grosse SD, Wittenberg E. Health utility elicitation: is there still a role for direct methods?. *Pharmacoeconomics*. 2012;30(2):83-86. doi:10.2165/11597720-000000000-00000
53. Rhodes ET, **Prosser LA**, Hoerger TJ, Lieu T, Ludwig DS, Laffel LM. Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus. *Diabet Med*. 2012;29(4):453-463.

doi:10.1111/j.1464-5491.2011.03542.x

54. Gidengil C, Lieu TA, Payne K, Rusinak D, Messonnier M, **Prosser LA**. Parental and societal values for the risks and benefits of childhood combination vaccines. *Vaccine*. 2012;30(23):3445-3452. doi:10.1016/j.vaccine.2012.03.022
55. Rhodes ET, Goran MI, Lieu TA, Lustig RH, **Prosser LA**, Songer TJ, Weigensberg MJ, Weinstock RS, Gonzalez T, Rawluk K, Zoghbi RM, Ludwig DS, Laffel LM. Health-related quality of life in adolescents with or at risk for type 2 diabetes mellitus. *J Pediatr*. 2012;160(6):911-917. doi:10.1016/j.jpeds.2011.11.026
56. Kimmel AD, Daniels N, Betancourt TS, Wood R, **Prosser LA**. Decision maker priorities for providing antiretroviral therapy in HIV-infected South Africans: a qualitative assessment. *AIDS Care*. 2012;24(6):778-792. doi:10.1080/09540121.2011.630366
57. Dempsey AF, Pangborn HM, **Prosser LA**. Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus. *Vaccine*. 2012;30(27):4060-4066. doi:10.1016/j.vaccine.2012.04.011
58. Song JW, Chung KC, **Prosser LA**. Treatment of ulnar neuropathy at the elbow: cost-utility analysis. *J Hand Surg Am*. 2012;37(8):1617-1629.e3. doi:10.1016/j.jhsa.2012.05.012
59. Zickafoose JS, DeCamp LR, Sambuco DJ, **Prosser LA**. Parents' preferences for enhanced access to the pediatric medical home: a qualitative study. *J Ambul Care Manage*. 2013;36(1):2-12. doi:10.1097/JAC.0b013e318276dc2f
60. Ungar WJ, **Prosser LA**, Burnett HF. Values and evidence colliding: health technology assessment in child health. *Expert Rev Pharmacoecon Outcomes Res*. 2013;13(4):417-419. doi:10.1586/14737167.2013.815420
61. Wittenberg E, Ritter GA, **Prosser LA**. Evidence of spillover of illness among household members: EQ-5D scores from a US sample. *Med Decis Making*. 2013;33(2):235-243. doi:10.1177/0272989X12464434
62. Vandorsten JP, Dodson WC, Espeland MA, Grobman WA, Guise JM, Mercer BM, Minkoff HL, Poindexter B, **Prosser LA**, Sawaya GF, Scott JR, Silver RM, Smith L, Thomas A, Tita AT. NIH consensus development conference: diagnosing gestational diabetes mellitus. *NIH Consens State Sci Statements*. 2013;29(1):1-31. Published 2013 Mar 6.
63. **Prosser LA**, Payne K, Rusinak D, Shi P, Messonnier M. Using a discrete choice experiment to elicit time trade-off and willingness-to-pay amounts for influenza health-related quality of life at different ages. *Pharmacoeconomics*. 2013;31(4):305-315. doi:10.1007/s40273-013-0029-6
64. Wittenberg E, **Prosser LA**. Disutility of illness for caregivers and families: a systematic review of the literature. *Pharmacoeconomics*. 2013;31(6):489-500. doi:10.1007/s40273-013-0040-y
65. Chang J, Freed GL, **Prosser LA**, Patel I, Erickson SR, Bagozzi RP, Balkrishnan R. Associations between physician financial incentives and the prescribing of anti-asthmatic medications in children in US outpatient settings. *J Child Health Care*. 2013;17(2):125-137. doi:10.1177/1367493512456110
66. Zickafoose JS, DeCamp LR, **Prosser LA**. Association between enhanced access services in pediatric primary care and utilization of emergency departments: a national parent survey. *J Pediatr*. 2013;163(5):1389-95.e956. doi:10.1016/j.jpeds.2013.04.050
67. Wittenberg E, Saada A, **Prosser LA**. How illness affects family members: a qualitative interview survey. *Patient*. 2013;6(4):257-268. doi:10.1007/s40271-013-0030-3
68. Sharp AL, **Prosser LA**, Walton M, Blow FC, Chermack ST, Zimmerman MA, Cunningham R. Cost analysis of youth violence prevention. *Pediatrics*. 2014;133(3):448-453. doi:10.1542/peds.2013-1615
69. Sears ED, Shin R, **Prosser LA**, Chung KC. Economic analysis of revision amputation and replantation treatment of finger amputation injuries. *Plast Reconstr Surg*. 2014;133(4):827-840. doi:10.1097/PRS.0000000000000019
70. Kemper AR, Green NS, Calonge N, Lam WK, Comeau AM, Goldenberg AJ, Ojodu J, **Prosser LA**, Tanksley S, Bocchini Jr JA. Decision-making process for conditions nominated to the recommended uniform screening

panel: statement of the US Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC). *Genet Med*. 2014;16(2):183-187. doi:10.1038/gim.2013.98

71. Chang J, Freed GL, **Prosser LA**, Patel I, Erickson SR, Bagozzi RP, Balkrishnan R. Comparisons of health care utilization outcomes in children with asthma enrolled in private insurance plans versus Medicaid [published correction appears in *J Pediatr Health Care*. 2014 Mar-Apr;28(2):185]. *J Pediatr Health Care*. 2014;28(1):71-79. doi:10.1016/j.pedhc.2012.11.001
72. Bärnighausen T, Berkley S, Bhutta ZA, Bishai DM, Black MM, Bloom DE, Constenla D, Driessen J, Edmunds J, Evans D, Griffiths U, Hansen P, Hashmani FN, Hutubessy R, Jamison DT, Jha P, Jit M, Johnson H, Laxminarayan R, Lee BY, Mhatre S, Mills A, Nordström A, Ozawa S, Prosser L, Silver K, Benn CS, Standaert B, Walker D. Reassessing the value of vaccines [published correction appears in *Lancet Glob Health*. 2014 Jun;2(6):e322]. *Lancet Glob Health*. 2014;2(5):e251-e252. doi:10.1016/S2214-109X(13)70170-0
73. Wright DR, Taveras EM, Gillman MW, Horan CM, Hohman KH, Gortmaker SL, **Prosser LA**. The cost of a primary care-based childhood obesity prevention intervention. *BMC Health Serv Res*. 2014;14:44. Published 2014 Jan 29. doi:10.1186/1472-6963-14-44
74. Lavelle TA, Weinstein MC, Newhouse JP, Munir K, Kuhlthau KA, **Prosser LA**. Economic burden of childhood autism spectrum disorders. *Pediatrics*. 2014;133(3):e520-e529. doi:10.1542/peds.2013-0763
75. Wright DR, **Prosser LA**. The impact of overweight and obesity on pediatric medical expenditures. *Appl Health Econ Health Policy*. 2014;12(2):139-150. doi:10.1007/s40258-014-0088-7
76. **Prosser LA**, Lamarand K, Gebremariam A, Wittenberg E. Measuring family HRQoL spillover effects using direct health utility assessment. *Med Decis Making*. 2015;35(1):81-93. doi:10.1177/0272989X14541328
77. Lipstein EA, Brinkman WB, Fiks AG, Hendrix KS, Kryworuchko J, Miller VA, **Prosser LA**, Ungar WJ, Fox D. An emerging field of research: challenges in pediatric decision making. *Med Decis Making*. 2015;35(3):403-408. doi:10.1177/0272989X14546901
78. Zickafoose JS, DeCamp LR, **Prosser LA**. Parents' preferences for enhanced access in the pediatric medical home: a discrete choice experiment. *JAMA Pediatr*. 2015;169(4):358-364. doi:10.1001/jamapediatrics.2014.3534
79. Nelson CP, Routh JC, Logvinenko T, Rosoklija I, Kokorowski PJ, **Prosser LA**, Schuster MA. Utility scores for vesicoureteral reflux and anti-reflux surgery. *J Pediatr Urol*. 2015;11(4):177-182. doi:10.1016/j.jpuro.2015.03.008
80. Harvey MJ, Gaies MG, **Prosser LA**. U.S. and International In-Hospital Costs of Extracorporeal Membrane Oxygenation: A Systematic Review. *Appl Health Econ Health Policy*. 2015;13(4):341-357. doi:10.1007/s40258-015-0170-9
81. Kemper AR, **Prosser LA**, Wade KC, Repka MX, Ying GS, Baumritter A, Quinn GE; e-ROP Study Cooperative Group. A Comparison of Strategies for Retinopathy of Prematurity Detection. *Pediatrics*. 2016;137(1):e20152256. doi:10.1542/peds.2015-2256
82. Goldenberg AJ, Comeau AM, Grosse SD, Tanksley S, **Prosser LA**, Ojodu J, Botkin JR, Kemper AR, Green NS. Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review. *Matern Child Health J*. 2016;20(3):693-700. doi:10.1007/s10995-015-1869-9
83. **Prosser LA**. Statistical Methods for the Analysis of Discrete-Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. *Value Health*. 2016;19(4):298-299. doi:10.1016/j.jval.2016.05.002
84. Cameron JI, Wittenberg E, **Prosser LA**. Caregivers and Families of Critically Ill Patients. *N Engl J Med*. 2016;375(10):1001. doi:10.1056/NEJMc1608225
85. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, **Prosser**

- LA**, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine [published correction appears in JAMA. 2016 Nov 8;316(18):1924. doi: 10.1001/jama.2016.15518]. *JAMA*. 2016;316(10):1093-1103. doi:10.1001/jama.2016.12195
86. Harvey MJ, **Prosser LA**, Messonnier ML, Hutton DW. Hitting the Optimal Vaccination Percentage and the Risks of Error: Why to Miss Right. *PLoS One*. 2016;11(6):e0156737. Published 2016 Jun 22. doi:10.1371/journal.pone.0156737
87. Rifas-Shiman SL, Taveras EM, Gortmaker SL, Hohman KH, Horan CM, Kleinman KP, Mitchell K, Price S, **Prosser LA**, Gillman MW. Two-year follow-up of a primary care-based intervention to prevent and manage childhood obesity: the High Five for Kids study. *Pediatr Obes*. 2017;12(3):e24-e27. doi:10.1111/ijpo.12141
88. Wittenberg E, **Prosser LA**. Health as a Family Affair. *N Engl J Med*. 2016;374(19):1804-1806. doi:10.1056/NEJMp1604456
89. Kemper AR, Brosco J, Comeau AM, Green NS, Grosse SD, Jones E, Kwon JM, Lam WK, Ojodu J, **Prosser LA**, Tanksley S. Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. *Genet Med*. 2017;19(1):121-126. doi:10.1038/gim.2016.68
90. Barbaro RP, Boonstra PS, Moler FW, Davis MM, **Prosser LA**. Hospital-level variation in inpatient cost among children receiving extracorporeal membrane oxygenation. *Perfusion*. 2017;32(7):538-546. doi:10.1177/0267659117702709
91. Tarini BA, Simon NJ, Payne K, Gebremariam A, Rose A, **Prosser LA**. An Assessment of Public Preferences for Newborn Screening Using Best-Worst Scaling. *J Pediatr*. 2018;201:62-68.e1. doi:10.1016/j.jpeds.2018.05.035
92. McGrady ME, **Prosser LA**, Thompson AN, Pai ALH. Application of a Discrete Choice Experiment to Assess Adherence-Related Motivation Among Adolescents and Young Adults with Cancer. *J Pediatr Psychol*. 2018;43(2):172-184. doi:10.1093/jpepsy/jsx104
93. **Prosser LA**. Defining the Value of Treatments of Rare Pediatric Conditions. *JAMA Pediatr*. 2018;172(12):1123-1124. doi:10.1001/jamapediatrics.2018.3343
94. Harvey MJ, Denton BT, **Prosser LA**, Hutton DW. Determining the optimal strategy for the live-attenuated herpes zoster vaccine in adults. *Vaccine*. 2018;36(41):6237-6247. doi:10.1016/j.vaccine.2018.06.059
95. Neumann PJ, Kim DD, Trikalinos TA, Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, **Prosser LA**, Owens DK, Meltzer DO, Kuntz KM, Krahn M, Feeny D, Basu A, Russell LB, Siegel JE, Ganiats TG, Sanders GD. Future Directions for Cost-effectiveness Analyses in Health and Medicine. *Med Decis Making*. 2018;38(7):767-777. doi:10.1177/0272989X18798833
96. Gauger TL, **Prosser LA**, Fontana M, Polverini PJ. Integrative and collaborative care models between pediatric oral health and primary care providers: a scoping review of the literature. *J Public Health Dent*. 2018;78(3):246-256. doi:10.1111/jphd.12267
97. Herman WH, Braffett BH, Kuo S, Lee JM, Brandle M, Jacobson AM, **Prosser LA**, Lachin JM. The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC). *J Diabetes Complications*. 2018;32(10):934-939. doi:10.1016/j.jdiacomp.2018.06.005
98. **Prosser LA**, Lam KK, Grosse SD, Casale M, Kemper AR. Using Decision Analysis to Support Newborn Screening Policy Decisions: A Case Study for Pompe Disease. *MDM Policy Pract*. 2018;3(1):2381468318763814. doi:10.1177/2381468318763814
99. Herman WH, Braffett BH, Kuo S, Lee JM, Brandle M, Jacobson AM, **Prosser LA**, Lachin JM. What are the clinical, quality-of-life, and cost consequences of 30years of excellent vs. poor glycemic control in type 1 diabetes?. *J Diabetes Complications*. 2018;32(10):911-915. doi:10.1016/j.jdiacomp.2018.05.007

100. Richardson JS, Messonnier ML, Prosser LA. Preferences for health economics presentations among vaccine policymakers and researchers. *Vaccine*. 2018;36(43):6416-6423. doi:10.1016/j.vaccine.2018.08.049
101. Huang Z, Sun X, Wagner AL, Ren J, Boulton ML, Prosser LA, Zikmund-Fisher BJ. Parent and caregiver perceptions about the safety and effectiveness of foreign and domestic vaccines in Shanghai, China. *PLoS One*. 2018;13(5):e0197437. Published 2018 May 21. doi:10.1371/journal.pone.0197437
102. Sun X, Huang Z, Wagner AL, Prosser LA, Xu E, Ren J, Wang B, Yan W, Zikmund-Fisher BJ. The role of severity perceptions and beliefs in natural infections in Shanghai parents' vaccine decision-making: A qualitative study. *BMC Public Health*. 2018;18(1):813. Published 2018 Jun 28. doi:10.1186/s12889-018-5734-9
103. Prosser LA, Wittenberg E. Advances in Methods and Novel Applications for Measuring Family Spillover Effects of Illness. *Pharmacoeconomics*. 2019;37(4):447-450. doi:10.1007/s40273-019-00794-5
104. Adams AS, Schmittiel JA, Altschuler A, Bayliss EA, Neugebauer R, Ma L, Dyer W, Clark J, Cook B, Willyoung D, Jaffe M, Young JD, Kim E, Boggs JM, Prosser LA, Wittenberg E, Callaghan B, Shainline M, Hippler RM, Grant RW. Automated symptom and treatment side effect monitoring for improved quality of life among adults with diabetic peripheral neuropathy in primary care: a pragmatic, cluster, randomized, controlled trial. *Diabet Med*. 2019;36(1):52-61. doi:10.1111/dme.13840
105. Lavelle TA, D'Cruz BN, Mohit B, Ungar WJ, Prosser LA, Tsiplova K, Vera-Llonch M, Lin PJ: Family spillover effects in pediatric cost-utility analyses. Family Spillover Effects in Pediatric Cost-Utility Analyses *Appl Health Econ Health Policy*. 2019;17(2):163-174. doi:10.1007/s40258-018-0436-0
106. Hutton DW, Rose A, Singer DC, Bridges CB, Kim D, Pike J, Prosser LA. Importance of reasons for stocking adult vaccines. *Am J Manag Care*. 2019;25(11):e334-e341. Published 2019 Nov 1.
107. Yagiela LM, Barbaro RP, Quasney MW, Pfarr MA, Ursu DC, Prosser LA, Odetola FO. Outcomes and Patterns of Healthcare Utilization After Hospitalization for Pediatric Critical Illness Due to Respiratory Failure. *Pediatr Crit Care Med*. 2019;20(2):120-127. doi:10.1097/PCC.0000000000001797
108. Lavelle TA, Weinstein MC, Newhouse JP, Munir K, Kuhlthau KA, Prosser LA. Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders. *Pharmacoeconomics*. 2019;37(4):541-551. doi:10.1007/s40273-019-00783-8
109. Rozier MD, Ghaferi AA, Rose A, Simon NJ, Birkmeyer N, Prosser LA. Patient Preferences for Bariatric Surgery: Findings from a Survey Using Discrete Choice Experiment Methodology. *JAMA Surg*. 2019;154(1):e184375. doi:10.1001/jamasurg.2018.4375
110. Rozier MD, Singh SR, Jacobson PD, Prosser LA. Priorities for Investing in Community Health Improvement: A Comparison of Decision Makers in Public Health, Nonprofit Hospitals, and Community Nonprofits. *J Public Health Manag Pract*. 2019;25(4):322-331. doi:10.1097/PHH.0000000000000848
111. Grosse SD, Prosser LA, Botkin JR. Screening for Neonatal Hyperbilirubinemia-First Do No Harm?. *JAMA Pediatr*. 2019;173(7):617-618. doi:10.1001/jamapediatrics.2019.1194
112. Wittenberg E, James LP, Prosser LA. Spillover Effects on Caregivers' and Family Members' Utility: A Systematic Review of the Literature. *Pharmacoeconomics*. 2019;37(4):475-499. doi:10.1007/s40273-019-00768-7
113. Tzilos Wernette G, Plegue M, Mmeje O, Sen A, Countryman K, Ngo Q, Prosser L, Zlotnick C. Reducing sexual health risks and substance use in the prenatal setting: A study protocol for a randomized controlled trial. *Contemp Clin Trials*. 2019;84:105827. doi:10.1016/j.cct.2019.105827
114. Chua KP, Brummett CM, Conti RM, Haffajee RL, Prosser LA, Bohnert ASB. Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids. *JAMA Netw Open*. 2019;2(5):e193673. Published 2019 May 3. doi:10.1001/jamanetworkopen.2019.3673
115. Grosse SD, Prosser LA, Botkin JR: Avoiding Harm From Hyperbilirubinemia Screening-Reply. *JAMA Pediatr*. 2019;173(12):1209-1210. doi:10.1001/jamapediatrics.2019.3762

116. Cunningham RM, Carter PM, Ranney ML, Walton M, Zeoli AM, Alpern ER, Branas C, Beidas RS, Ehrlich PF, Goyal MK, Goldstick JE, Hemenway D, Hargarten SW, King CA, Massey L, Ngo Q, Pizarro J, Prosser L, Rowhani-Rahbar A, Rivara F, Rupp LA, Sigel E, Savolainen J, Zimmerman MA. Prevention of Firearm Injuries Among Children and Adolescents: Consensus-Driven Research Agenda from the Firearm Safety Among Children and Teens (FACTS) Consortium *JAMA Pediatr.* 2019;173(8):780-789. doi:10.1001/jamapediatrics.2019.1494
117. Rose AM, Grosse SD, Garcia SP, Bach J, Kleyn M, Simon NE, **Prosser LA**. The financial and time burden associated with phenylketonuria treatment in the United States. *Mol Genet Metab Rep.* 2019;21:100523. Published 2019 Oct 16. doi:10.1016/j.ymgmr.2019.100523
118. **Prosser LA**, Harpaz R, Rose AM, Gebremariam A, Guo A, Ortega-Sanchez IR, Zhou F, Dooling K. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. *Ann Intern Med.* 2019;170(6):380-388. doi:10.7326/M18-2347
119. Simon NJ, Richardson J, Ahmad A, Rose A, Wittenberg E, D'Cruz B, **Prosser LA**. Health utilities and parental quality of life effects for three rare conditions tested in newborns. *J Patient Rep Outcomes.* 2019;3(1):4. Published 2019 Jan 22. doi:10.1186/s41687-019-0093-6
120. Goodman RM, Bridges CB, Kim D, Pike J, Rose A, **Prosser LA**, Hutton DW. Billing and payment of commercial and Medicaid health plan adult vaccination claims in Michigan since the Affordable Care Act. *Vaccine.* 2019;37(45):6803-6813. doi:10.1016/j.vaccine.2019.09.042
121. Lavelle TA, Messonnier M, Stokley S, Kim D, Ramakrishnan A, Gebremariam A, Simon NE, Rose AM, **Prosser LA**. Use of a choice survey to identify adult, adolescent and parent preferences for vaccination in the United States. *J Patient Rep Outcomes.* 2019;3(1):51. Published 2019 Jul 29. doi:10.1186/s41687-019-0135-0
122. Harvey M, **Prosser LA**, Rose AM, Ortega-Sanchez IR, Harpaz R. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition. *Pain.* 2020;161(2):361-368. doi:10.1097/j.pain.0000000000001718
123. Rozier MD, Ghaferi AA, Rose AM, Simon NJ, Birkmeyer NJ, **Prosser LA**. Preferences for bariatric surgery: comparing surgeons and patients using a discrete choice experiment. *Surg Obes Relat Dis.* 2020;16(6):738-744. doi:10.1016/j.soard.2020.02.005
124. Barton CM, Alberti M, Ames D, Atkinson JA, Bales J, Burke E, Chen M, Diallo SY, Earn DJD, Fath B, Feng Z, Gibbons C, Hammond R, Heffernan J, Houser H, Hovmand PS, Kopainsky B, Mabry PL, Mair C, Meier P, Niles R, Nosek B, Osgood N, Pierce S, Polhill JG, Prosser L, Robinson E, Rosenzweig C, Sankaran S, Stange K, Tucker G. Call for transparency of COVID-19 models. *Science.* 2020;368(6490):482-483. doi:10.1126/science.abb8637
125. Huang Z, Wagner AL, Lin M, Sun X, Zikmund-Fisher BJ, Boulton ML, Ren J, **Prosser LA**. Preferences for vaccination program attributes among parents of young infants in Shanghai, China. *Hum Vaccin Immunother.* 2020;16(8):1905-1910. doi:10.1080/21645515.2020.1712937
126. Sun X, Wagner AL, Ji J, Huang Z, Zikmund-Fisher BJ, Boulton ML, Ren J, **Prosser LA**. A conjoint analysis of stated vaccine preferences in Shanghai, China. *Vaccine.* 2020;38(6):1520-1525. doi:10.1016/j.vaccine.2019.11.062
127. Richardson JS, Kemper AR, Grosse SD, Lam WKK, Rose AM, Ahmad A, Gebremariam A, **Prosser LA**. Health and economic outcomes of newborn screening for infantile-onset Pompe disease. *Genet Med.* 2021;23(4):758-766. doi:10.1038/s41436-020-01038-0
128. Wagner AL, Huang Z, Ren J, Laffoon M, Ji M, Pinckney LC, Sun X, **Prosser LA**, Boulton ML, Zikmund-Fisher BJ. Vaccine Hesitancy and Concerns About Vaccine Safety and Effectiveness in Shanghai, China. *Am J Prev Med.* 2021;60(1 Suppl 1):S77-S86. doi:10.1016/j.amepre.2020.09.003
129. McGrady ME, Pai ALH, **Prosser LA**. Using discrete choice experiments to develop and deliver patient-centered psychological interventions: a systematic review. *Health Psychol Rev.* 2021;15(2):314-332.

doi:10.1080/17437199.2020.1715813

130. Chua KP, DeJonckheere M, Reeves SL, Tribble AC, **Prosser LA**. Factors Associated With School Attendance Plans and Support for COVID-19 Risk Mitigation Measures Among Parents and Guardians. *Acad Pediatr*. 2021;21(4):684-693. doi:10.1016/j.acap.2020.11.017
131. Lavelle TA, Wittenberg E, Lamarand K, **Prosser LA**. Variation in the spillover effects of illness on parents, spouses, and children of the chronically ill. *Appl Health Econ Health Policy*. 2014;12(2):117-124. doi:10.1007/s40258-014-0079-8
132. Eisman AB, Hutton DW, **Prosser LA**, Smith SN, Kilbourne AM. Cost-effectiveness of the Adaptive Implementation of Effective Programs Trial (ADEPT): approaches to adopting implementation strategies. *Implement Sci*. 2020;15(1):109. Published 2020 Dec 14. doi:10.1186/s13012-020-01069-w
133. Avanceña ALV, **Prosser LA**. Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review. *Value Health*. 2021;24(1):136-143. doi:10.1016/j.jval.2020.10.010
134. Richardson JS, Kemper AR, Grosse SD, Lam WKK, Rose AM, Ahmad A, Gebremariam A, **Prosser LA**. Health and economic outcomes of newborn screening for infantile-onset Pompe disease. *Genet Med*. 2021;23(4):758-766. doi:10.1038/s41436-020-01038-0
135. Steimle LN, Havumaki J, Eisenberg MC, Eisenberg JNS, **Prosser LA**, Pike J, Ortega-Sanchez IR, Mattison CP, Hall AJ, Steele MK, Lopman BA, Hutton DW. Cost-effectiveness of pediatric norovirus vaccination in daycare settings. *Vaccine*. 2021;39(15):2133-2145. doi:10.1016/j.vaccine.2021.02.066
136. Hutton DW, McCullough JS, Prosser L, Ye W, Herman WH, Zhang P, Pilishvili T, Pike J. Cost implications of pneumococcal vaccination of adults aged 30–60 with a recent diagnosis of diabetes. *Vaccine*. 2021;39(8):1333-1338. doi:10.1016/j.vaccine.2020.11.060
137. Crossnohere NL, Fisher R, Lloyd A, **Prosser LA**, Bridges JFP. Assessing the Appropriateness of the EQ-5D for Duchenne Muscular Dystrophy: A Patient-Centered Study. *Med Decis Making*. 2021;41(2):209-221. doi:10.1177/0272989X20978390
138. Chen HF, Rose AM, Waisbren S, Ahmad A, **Prosser LA**. Newborn Screening and Treatment of Phenylketonuria: Projected Health Outcomes and Cost-Effectiveness. *Children (Basel)*. 2021;8(5):381. Published 2021 May 12. doi:10.3390/children8050381
139. Cernat A, Hayeems RZ, **Prosser LA**, Ungar WJ. Incorporating Cascade Effects of Genetic Testing in Economic Evaluation: A Scoping Review of Methodological Challenges. *Children (Basel)*. 2021;8(5):346. Published 2021 Apr 27. doi:10.3390/children8050346
140. Bonar E, Bohnert A, Carter P, Clark S, Kidwell K, King C, Losman E, McCabe S, Prosser L, Walton M. 0024 Feasibility and acceptability of telemedicine and patient portal interventions to prevent opioid misuse in adolescents and young adults in the emergency department. *Inj Prev*. March 2021:A4.2-A4. doi:10.1136/injuryprev-2021-savir.10
141. Shih SF, Wagner AL, Masters NB, **Prosser LA**, Lu Y, Zikmund-Fisher BJ. Vaccine Hesitancy and Rejection of a Vaccine for the Novel Coronavirus in the United States. *Front Immunol*. 2021;12:558270. Published 2021 Jun 14. doi:10.3389/fimmu.2021.558270
142. Grosse SD, Kemper AR, **Prosser LA**. Data Needs for Economic Evaluations of Screening in Pediatric Primary Care: A Research Framework. *Pediatrics*. 2021;148(Suppl 1):s45-s50. doi:10.1542/peds.2021-050693J
143. Bonar EE, Kidwell KM, Bohnert ASB, Bourque CA, Carter PM, Clark SJ, Glantz MD, King CA, Losman ED, McCabe SE, Philyaw-Kotov ML, **Prosser LA**, Voepel-Lewis T, Zheng K, Walton MA. Optimizing scalable, technology-supported behavioral interventions to prevent opioid misuse among adolescents and young adults in the emergency department: A randomized controlled trial protocol. *Contemp Clin Trials*. 2021;108:106523. doi:10.1016/j.cct.2021.106523
144. Carlton EF, Weiss SL, Prescott HC, **Prosser LA**. What's the Cost? Measuring the Economic Impact of Pediatric

- Sepsis. *Front Pediatr*. 2021;9:761994. Published 2021 Nov 15. doi:10.3389/fped.2021.761994
145. Avanceña ALV, **Prosser LA**. Innovations in cost-effectiveness analysis that advance equity can expand its use in health policy. *BMJ Global Health*. 2022;7(2):e008140. doi:10.1136/bmjgh-2021-008140
  146. Janusz CB, Anderson TC, Leidner AJ, Lee GM, Dooling K, **Prosser LA**: Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults. *Hum Vaccin Immunother*. 2022;18(5):2060668. doi:10.1080/21645515.2022.2060668
  147. Chow AJ, Iverson R, Lamoureux M, Tingley K, Jordan I, Pallone N, Smith M, Al-Baldawi Z, Chakraborty P, Brehaut J, Chan A, Cohen E, Dyack S, Gillis LJ, Goobie S, Graham ID, Greenberg CR, Grimshaw JM, Hayeems RZ, Jain-Ghai S, Jolly A, Khangura S, MacKenzie JJ, Major N, Mitchell JJ, Nicholls SG, Pender A, Potter M, Prasad C, **Prosser LA**, Schulze A, Siriwardena K, Sparkes R, Speechley K, Stockler S, Taljaard M, Teitelbaum M, Trakadis Y, van Karnebeek C, Walia JS, Wilson BJ, Wilson K, Potter BK. Families' healthcare experiences for children with inherited metabolic diseases: protocol for a mixed methods cohort study. *BMJ Open*. 2022;12(2):e055664. Published 2022 Feb 22. doi:10.1136/bmjopen-2021-055664
  148. Dunlap LJ, Kuklinski MR, Cowell A, McCollister KE, Bowser DM, Campbell M, Fernandes CF, Kemburu P, Livingston BJ, **Prosser LA**, Rao V, Smart R, Yilmazer T. Economic Evaluation Design within the HEAL Prevention Cooperative. *Prev Sci*. 2023;24(Suppl 1):50-60. doi:10.1007/s11121-022-01400-5
  149. Carlton EF, Gebremariam A, Maddux AB, McNamara N, Barbaro RP, Cornell TT, Iwashyna TJ, **Prosser LA**, Zimmerman J, Weiss S, Prescott HC. New and Progressive Medical Conditions After Pediatric Sepsis Hospitalization Requiring Critical Care. *JAMA Pediatr*. 2022;176(11):e223554. doi:10.1001/jamapediatrics.2022.3554
  150. Omari A, Reeves SL, **Prosser LA**, Creary MS, Ahmad A, Chua KP. Usability of NewSTEPs Data for Assessing the Characteristics of Infants with Newborn Screening Disorders. *Int J Neonatal Screen*. 2022;8(3):42. Published 2022 Jul 19. doi:10.3390/ijns8030042
  151. Wagner AL, Lu Y, Janusz CB, Pan SW, Glover B, Wu Z, **Prosser LA**. Preferences for Sexually Transmitted Infection and Cancer Vaccines in the United States and in China. *Value Health*. 2023;26(2):261-268. doi:10.1016/j.jval.2022.07.019
  152. **Prosser LA**, Wagner AL, Wittenberg E, Zikmund-Fisher BJ, Rose AM, Pike J. A Discrete Choice Analysis Comparing COVID-19 Vaccination Decisions for Children and Adults. *JAMA Netw Open*. 2023;6(1):e2253582. Published 2023 Jan 3. doi:10.1001/jamanetworkopen.2022.53582
  153. Cadham CJ, **Prosser LA**. Eliciting Trade-Offs Between Equity and Efficiency: A Methodological Scoping Review. *Value Health*. 2023;26(6):943-952. doi:10.1016/j.jval.2023.02.006
  154. Kim DD, Do LA, Synnott PG, Lavelle TA, **Prosser LA**, Wong JB, Neumann PJ. Developing Criteria for Health Economic Quality Evaluation Tool. *Value Health*. 2023;26(8):1225-1234. doi:10.1016/j.jval.2023.04.004
  155. Leidner AJ, Anderson TC, Hong K, Ortega-Sanchez IR, Guo A, Pike J, **Prosser LA**, Dooling KL. Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years. *Value Health*. 2023;26(2):204-215. doi:10.1016/j.jval.2022.08.003
  156. Ream MA, Lam WKK, Grosse SD, Ojodu J, Jones E, **Prosser LA**, Rosé AM, Comeau AM, Tanksley S, Powell CM, Kemper AR. Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States. *Genet Med*. 2023;25(2):100330. doi:10.1016/j.gim.2022.10.012
  157. Deluca EK, Gebremariam A, Rose A, Biggerstaff M, Meltzer MI, **Prosser LA**: Cost-effectiveness of routine annual influenza vaccination by age and risk status. *Vaccine*. 2023;41(29):4239-4248. doi:10.1016/j.vaccine.2023.04.069
  158. Carlton EF, Moniz MH, Scott JW, Prescott HC, **Prosser LA**, Becker NV. Preexisting Financial Hardship Among Caregivers of Hospitalized Children. *JAMA Pediatr*. 2023;177(7):732-733. doi:10.1001/jamapediatrics.2023.0638

159. Ream MA, Lam WKK, Grosse SD, Ojodu J, Jones E, **Prosser LA**, Rose AM, Comeau AM, Tanksley S, Powell CM, Kemper AR. Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening. *Pediatrics*. 2023;152(2):e2023062100. doi:10.1542/peds.2023-062100
160. Doan TT, DeJonckheere M, Wright DR, Hutton DW, **Prosser LA**. Preferences and experiences of pediatricians on implementing national guidelines on universal routine screening of adolescents for major depressive disorder: A qualitative study. *Compr Psychiatry*. 2023;127:152412. doi:10.1016/j.comppsy.2023.152412
161. Henry E, Al-Janabi H, Brouwer W, Cullinan J, Engel L, Griffin S, Hulme C, Kingkaew P, Lloyd A, Payakachat N, Pennington B, Peña-Longobardo LM, **Prosser LA**, Shah K, Ungar WJ, Wilkinson T, Wittenberg E. Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force. *Pharmacoeconomics*. 2024;42(3):343-362. doi:10.1007/s40273-023-01321-3
162. Avanceña ALV, Rose AM, Gardner MD, Rutter MM, Schafer-Kalkhoff T, Suorsa-Johnson KI, van Leeuwen KD, Weidler EM, Gebremariam A, Sandberg DE, **Prosser LA**. Preferences in Clinical Care of Individuals With Differences of Sex Development. *Pediatrics*. 2024;153(6):e2023064207. doi:10.1542/peds.2023-064207
163. Janusz CB, Doan T, Gebremariam A, Rose A, Keels MA, Quinonez RB, Eckert G, Yanca E, Fontana M, **Prosser LA**. A Cost-Effectiveness Analysis of Population-Level Dental Caries Prevention Strategies in US Children. *Acad Pediatr*. 2024;24(5):765-775. doi:10.1016/j.acap.2024.02.006
164. Kim DeLuca E, Dalziel K, Wittenberg E, Henderson NC, **Prosser LA**. Selecting PedsQL items to derive the PedsUtil health state classification system to measure health utilities in children. *Health and Quality of Life Outcomes*. 2024;22(1):53. Published 2024 Jul 10. doi:10.1186/s12955-024-02268-5
165. Hutton DW, **Prosser LA**, Rose AM, Mercon K, Ortega-Sanchez IR, Leidner AJ, McMorro ML, Fleming-Dutra KE, Prill MM, Pike J, Jones JM. Cost-Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness. *Pediatrics*. 2024;154(6):e2024066481. doi:10.1542/peds.2024-066481
166. Hutton DW, **Prosser LA**, Rose AM, Mercon K, Ortega-Sanchez IR, Leidner AJ, McMorro ML, Fleming-Dutra KE, Prill MM, Pike J, Jones JM. Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children. *Pediatrics*. 2024;154(6):e2024066461. doi:10.1542/peds.2024-066461
167. Hutton DW, **Prosser LA**, Rose AM, Mercon K, Ortega-Sanchez IR, Leidner AJ, Havers FP, Prill MM, Whitaker M, Roper LE, Pike J, Britton A, Melgar M. Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus. *Vaccine*. 2024;42(24):126294. doi:10.1016/j.vaccine.2024.126294
168. Kim DeLuca E, Dalziel K, Wittenberg E, Rose AM, **Prosser LA**. Deriving the PedsUtil health state classification system to measure health utilities for pediatric populations based on the PedsQL: a confirmatory factor analysis. *Health Qual Life Outcomes*. 2024 Oct;22(1):85 Published 2024 Oct 8. doi:10.1186/s12955-024-02300-8
169. Doan TT, Hutton DW, Wright DR, **Prosser LA**. Estimating Transition Probabilities for Modeling Major Depression in Adolescents by Sex and Race or Ethnicity Combinations in the USA. *Appl Health Econ Health Policy*. 2024;22(3):375-390. doi:10.1007/s40258-024-00872-6
170. Mercon KR, Rose AM, Cadham CJ, Gebremariam A, Pike J, Wittenberg E, **Prosser LA**. Health Preferences in Transition: Differences from Pandemic to Post-Pandemic in Valuation of COVID-19 and RSV Illness in Children and Adults. *Children (Basel)*. 2025 Jan 31;12(2):181. doi: 10.3390/children12020181.
171. **Prosser LA**, Perroud J, Chung GS, Gebremariam A, Janusz CB, Mercon K, Rose AM, Avañcena ALV, Kim DeLuca E, Hutton DW. The cost-effectiveness of vaccination against COVID-19 illness during the initial year of vaccination. *Vaccine*. 2025 Feb 27;43:126725. doi: 10.1016/j.vaccine.2025.126725.
172. Ream MA, Lam WKK, Grosse SD, Ojodu J, Jones E, **Prosser LA**, Rose AM, Comeau AM, Tanksley S, DiCostanzo KP, Kemper AR. Evidence for Infantile Krabbe Disease Newborn Screening. *Pediatrics*. 2025 Apr 1;155(4):e2024069152. doi: 10.1542/peds.2024-069152.
173. Doan TT, Hutton DW, Wright DR, **Prosser LA**. Cost-Effectiveness of Universal Routine Depression Screening

for Adolescents in Primary Care. *JAMA Health Forum*. 2025 May 2;6(5):e250711. doi: 10.1001/jamahealthforum.2025.0711.

174. Jacob V, Reynolds JA, Chattopadhyay SK, Hopkins DP, Peterson C, Tenney B, Nadal N, Cuellar AE, **Prosser LA**, Clymer JM, Stoddard SA; Community Preventive Services Task Force. Family-Based Interventions to Prevent Substance Use Among Youth: Community Guide Systematic Economic Review. *American Journal of Preventive Medicine*. 2025 Jul;69(1):107639. doi: 10.1016/j.amepre.2025.04.009.
175. **Prosser LA**, Wallace M, Rose AM, Mercon K, Janusz CB, Gebremariam A, Hutton DW, Leidner AJ, Zhou F, Ortega-Sanchez IR, Moulia D, Link-Gelles R, Saydah S, Shah M, Pike J. Cost-effectiveness analysis of 2023-2024 COVID-19 vaccination in adults. *JAMA Network Open*. 2025 Aug 1;8(8):e2523688. doi: 10.1001/jamanetworkopen.2025.23688.
176. Rose AM, Mercon KR, Gebremariam A, Pike J, **Prosser LA**. Out-of-pocket costs, time burden, and caregiver quality of life associated with pediatric medically attended respiratory syncytial virus illnesses. *Cost Effectiveness and Resource Allocation*. 2025 Aug 12;23(1):42. doi: 10.1186/s12962-025-00646-4.
177. Doan TT, Wright DR, DeJonckheere M, Hutton DW, Ray KN, **Prosser LA**. Physician Preferences for Universal Routine Depression Screening for Adolescents in Primary Care. *JAMA Network Open*. 2025 Nov 3;8(11):e2545361. doi: 10.1001/jamanetworkopen.2025.45361.
178. Matza LS, Rowen D, Chandler F, Dalziel K, Ghabri S, Law EH, **Prosser LA**, Rivero-Arias O, Shah K, Stolk E, Wolff J, Devlin N. Valuing Child and Adolescent Health States to Derive Utilities for Use in Economic Evaluation: A Good Practices Report of an ISPOR Task Force. *Value Health*. 2026 Apr;29(4):535-546. doi: 10.1016/j.jval.2025.12.016.
179. **Prosser LA**, Hutton DW. When Cost-Effectiveness Crosses Borders-Nirsevimab as an Example. *JAMA Pediatrics*. 2026 Apr 13. doi: 10.1001/jamapediatrics.2026.0823. Epub ahead of print.
180. Hsieh HM, Yang WC, Jong YJ, Chen HF, **Prosser LA**. Cost-Effectiveness of Universal Newborn Screening and Disease-Modifying Therapies for Spinal Muscular Atrophy in Taiwan. *Value in Health*. In Press.
181. Streur CS, Elased D, Kreschmer JM, Parten R, Alhazmi H, Gay B, DUBY A, Schmalfluss H, Goldstein J, Holmbeck GN, **Prosser LA**, Bridges JFP. Developing and Piloting an Instrument to Prioritize the Worries of Female Youth with a Physical Disability and Mothers During the Transition to Adulthood. *MDM Policy & Practice*. In Press

### **Book Chapters**

1. **Prosser LA**, Payne K: Discrete Choice. Encyclopedia of Medical Decision Making, Kattan, MW SAGE Publications, Thousand Oaks, CA, 2009
2. Neumann PJ, Russell LB, Siegel JE, **Prosser LA**, Krahn M, Mandelblatt JS, Daniels N, Gold MR: Chapter 1: Using Cost-Effectiveness in Health and Medicine. Cost-Effectiveness in Health and Medicine, Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG Oxford University Press, 2017. 2, 1-38
3. Feeny D, Krahn M, **Prosser LA**, Salomon JA: Chapter 7: Valuing Health Outcomes. Cost-Effectiveness in Health and Medicine, Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG Oxford University Press, 2017. 2, 167-200
4. **Prosser LA**, Neumann PJ, Sanders GD, Siegel JE: Chapter 13: Reporting Cost-Effectiveness Analyses. Cost-Effectiveness in Health and Medicine, Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG Oxford University Press, 2017. 2, 343-368

### **Reports**

1. Pearson SD, Ladapo J, **Prosser LA**. Intensity modulated radiation therapy (IMRT) for localized prostate cancer. Final appraisal document. Institute for Clinical and Economic Review. November, 2007. Available at: <http://www.icer-review.org/index.php/imrt.html>.

2. Evidence Review: Pompe Disease. Prepared for: Maternal and Child Health Bureau. 2008. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/pompe-evidence-review-report-2008.pdf>.
3. Evidence Review: Krabbe Disease. Prepared for: Maternal and Child Health Bureau. 2009. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/krabbe-disease-evidence-review-report.pdf>.
4. Evidence Review: Severe Combined Immunodeficiency (SCID). Prepared for: Maternal and Child Health Bureau. 2009. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/scid-external-evidence-review-report.pdf>.
5. Evidence Review: Critical Congenital Cyanotic Heart Disease (CCCHD). Prepared for: Maternal and Child Health Bureau. 2010. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/cyanotic-heart-external-evidence-review-report.pdf>.
6. Evidence Review: Neonatal Hyperbilirubinemia. Prepared for: Maternal and Child Health Bureau. 2012. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/hyperbilirubinemia-evidence-review-report.pdf>.
7. Evidence Report: Newborn Screening for Pompe Disease. Prepared for: Maternal and Child Health Bureau. 2013. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/pompe-external-evidence-review-report-2013.pdf>.
8. Newborn Screening for Mucopolysaccharidosis Type 1 (MPS I): A Systematic Review of Evidence. Prepared for: Maternal and Child Health Bureau. 2015. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/mps1-external-evidence-review-report.pdf>.
9. Newborn Screening for X-Linked Adrenoleukodystrophy (X-ALD): A Systematic Review of Evidence. Prepared for: Maternal and Child Health Bureau. 2017. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/xald-external-evidence-review-report.pdf>.
10. Evidence-Based Review of Newborn Screening for Spinal Muscular Atrophy (SMA): Final Report (v5.2). Prepared for: Maternal and Child Health Bureau. 2018. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/reports-recommendations/sma-final-report.pdf>
11. Guidance for Health Economics Studies Presented to the Advisory Committee on Immunization Practices (ACIP), 2019 Update. Prepared for: Centers for Disease Control and Prevention. 2019. Available at: <https://www.cdc.gov/vaccines/acip/committee/downloads/Economics-Guidance-for-ACIP-2019.pdf>
12. Evidence-Based Review of Newborn Screening for Guanidinoacetate Methyltransferase (GAMT) Deficiency: Final Report. Prepared for: Maternal and Child Health Bureau. 2022. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/meetings/gamt-deficiency-final-report.pdf>
13. Evidence-Based Review of Newborn Screening for Mucopolysaccharidosis Type II: Final Report. Prepared for: Maternal and Child Health Bureau. 2022. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/meetings/mps-ii-final-report-3-28-2022.pdf>
14. Evidence-Based Review of Newborn Screening for Krabbe Disease: Final Report. Prepared for: Maternal and Child Health Bureau. 2023. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/resources/krabbe-disease-erg-report.pdf>

15. Guidelines for the Economic Evaluation of Vaccination Programs in Canada. Prepared for: National Advisory Committee on Immunization (NACI). 2023. Available at: <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/methods-process/incorporating-economic-evidence-federal-vaccine-recommendations/guidelines-evaluation-vaccination-programs-canada.pdf>

### **Theses**

1. **Prosser LA.** Pharmaceutical research and development: the effects of increased competition on human resource strategies [master's thesis]. Boston (MA): Massachusetts Institute of Technology (MIT); 1992.
2. **Prosser LA.** Patient preferences and economic considerations in treatment decisions for multiple sclerosis [dissertation]. Cambridge (MA): Harvard University; 2000.

### **Other Media**

1. Screening for MCADD Outweighs Risks, UPI.com, 2010.
2. Benefits Outweigh Risks Associated with Newborn Screening for Disorder, Science Daily, 2010.
3. Newborn Screening, Public Health Minute, 2015.
4. New Set of Recommendations Developed to Improve Quality of Cost-effectiveness Analyses, Science Daily, 2016.
5. Lisa Prosser contributes to new guidelines on evidence-based health care, U-M Institute for Healthcare Policy & Innovation Press Release, 2016.
6. What's it worth? New shingles vaccine offers a chance to measure the value of prevention, Michigan Medicine Health Lab Blog, 2017.
7. CAR T-Cell Therapy Cost-Effective in Pediatric Leukemia. MedPage Today. 2018.
8. Cost and Weight-Loss Potential Matter Most to Bariatric Surgery Patients. Michigan Medicine Health Lab Blog. 2018.
9. Decisions, decisions: Using research translation to inform health policy options amid uncertainty, U-M Institute for Healthcare Policy & Innovation Blog, 2018.
10. Examining Public Opinions About Expanded Newborn Screenings, Michigan Medicine Health Lab Blog, 2018.
11. Opioid "Doctor Shoppers" May Not Have to Look Far for Drugs, Michigan Medicine Health Lab Blog, 2019.
12. To protect children and teens from firearm harm, research on these 26 questions should be done first, experts say, Michigan Medicine Health Lab Blog, 2019.
13. SMDM COVID-19 Decision Modeling Grant, U-M Institute for Healthcare Policy & Innovation Press Release, 2020.
14. Children commonly face new, worsening health problems months after critical illness from sepsis, Michigan Medicine Health Lab Blog, 2022.
15. Expert Q&A: Exploring the cost-effectiveness of RSV vaccines in older adults, U-M Institute for Healthcare Policy & Innovation Blog, 2023.
16. New COVID-19 vaccine a good value for U.S., U-M team finds, Michigan Medicine Health Lab Blog, 2023.
17. New RSV vaccine for older adults can result in individual and societal cost savings, benefits, U-M Institute for Healthcare Policy & Innovation Press Release, 2024.
18. Q&A: Prosser and team find updated COVID-19 vaccine more cost-effective for older adults, U-M Institute for Healthcare Policy & Innovation Blog, 2024.

19. Broad COVID-19 vaccination makes economic sense, especially for older adults, study finds, Michigan Medicine Health Lab Blog, 2025.
20. Investing in COVID-19 vaccination more than paid off for U.S., study finds, Michigan Medicine Health Lab Blog, 2025.
21. U-M study: Investing in COVID-19 vaccine paid off for U.S., U-M The University Record Newsletter, 2025.

### **Podcast**

1. **Prosser, L:** Why Some Forgo the Flu Shot, National Public Radio, 2006.
2. **Prosser, L:** Widespread COVID-19 vaccination would save lives, and money, Michigan Medicine Health Lab Podcast, 2025

### **Abstracts**

**Note: This section only includes abstracts since 2016.**

1. **Prosser LA,** Grosse SD, Casale MT, Lam KK, Kemper A. Population Level Outcomes for Newborn Screening for Pompe Disease Compared with Clinical Identification. Pediatric Academic Societies Annual Meeting, April 29-May 3, 2016, Baltimore, MD.
2. Tarini B, Gebremariam A, Simon N, **Prosser LA.** Using Best-worst Scaling to Measure Public Values for Newborn. Pediatric Academic Societies Annual Meeting, April 29-May 3, 2016, Baltimore, MD.
3. Barbaro RP, **Prosser LA,** Paden ML, Moler FW, Davis MM. Variation in Hospital Costs among Children Requiring Extracorporeal Membrane Oxygenation. Pediatric Academic Societies Annual Meeting, April 29-May 2016, Baltimore, MD.
4. Lavelle T, Messonnier ML, Stokley S, Gebremariam A, Simon NJ, Rose A, **Prosser LA.** Using Conjoint Analysis to Identify Factors that Influence Vaccine Acceptance. Society for Medical Decision Making Annual Meeting, October 2016, Vancouver, British Columbia, Canada.
5. Richardson JS, Wittenberg E, **Prosser LA.** Health Utilities of Rare Heritable Disorders: Approaches for Health State Descriptions and Measuring Spillover Effects on Family Members. Society for Medical Decision Making Annual Meeting, October 2016, Vancouver, British Columbia, Canada.
6. Hutton DW, **Prosser LA.** Cost-effectiveness of Expanded Adolescent HPV Vaccine Coverage. Presented at the 38th Annual Meeting of the Society for Medical Decision Making, October 23-26, 2016, Vancouver, Canada.
7. Richardson JS, **Prosser LA,** Messonnier ML. Preferences for Health Economics Presentations Among Vaccine Policy Makers and Researchers. Presented at the 38th Annual Meeting of the Society for Medical Decision Making, October 23-26, 2016, Vancouver, Canada.
8. **Prosser LA,** Richardson J, Rose A, Kemper A. Health and Economic Outcomes of Newborn Screening for Pompe Disease. Annual Meeting of the Pediatric Academic Societies, May 2017, San Francisco, CA.
9. Rose A, Elmlblad N, Bridges C, Kim D, **Prosser LA,** Hutton D. Attributes important to physicians in the decision to stock adult vaccines. National Adult Immunization Summit. May 2017. Atlanta, GA.
10. Goodman R, Bridges C, Kim D, Pike J, Rose A, **Prosser LA,** Hutton D. Rates of commercial and Medicaid health plan non-payment of adult vaccine dose claims. National Adult Immunization Summit. May 2017. Atlanta, GA.
11. Pike J, Rose A, **Prosser LA,** Hutton D. Patterns of pneumococcal vaccination in incident diabetics. National Adult Immunization Summit. May 2017. Atlanta, GA.
12. Richardson JS, Hutton D, **Prosser LA,** King C, Eisenberg D, McCullough J. Medical Costs Associated with Grief and Bereavement. Society for Medical Decision Making Annual Meeting, October 2017, Pittsburgh, PA.

13. Lavelle T, D’Cruz, Mohit B, Ungar WJ, **Prosser LA**, Tsiplova K, Montserrat-Llonch V, Lin PJ. Family Cost and Health Effects in Pediatric Cost-Effectiveness Analyses. Society for Medical Decision Making Annual Meeting, October 2018, Montreal, Quebec, Canada.
14. Wagner A, Sun S, Boulton M, Huang Z, Ren J, Zikmund-Fisher BJ, **Prosser L**. Preferences for Vaccine and Vaccination Program Attributes Among Parents in Shanghai, China. Society for Medical Decision Making Annual Meeting, October 2018, Montreal, Quebec, Canada.
15. Chen HF, Rose A, **Prosser LA**. Cost-Effectiveness Analysis of Newborn Screening and Treatment of Phenylketonuria. Society for Medical Decision Making Annual Meeting, October 2018, Montreal, Quebec, Canada.
16. Wright DR, Zhou C, Scherer AM, Lipstein E, **Prosser LA**. Using Machine Learning Models to Predict Memberships in Best-Worst Scaling Latent Classes. Society for Medical Decision Making Annual Meeting, October 2018, Montreal, Quebec, Canada.
17. Hutton DW, Singer D, Bridges C, Kim D, Pike J, Rose A, **Prosser LA**. Importance of Reasons for Stocking Adult Vaccines. Society for Medical Decision Making Annual Meeting, October 2018, Montreal, Quebec, Canada.
18. **Prosser LA**, Rose AR, Harpaz R, Dooling K. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. Accepted for poster presentation at the AcademyHealth 2019 Annual Research Meeting, June 2019, Washington, DC.
19. Doan TT, Rose AM, Gebremariam A, Fontana M, Yanca ER, Kimmel L, Keels MA, Quinonez RB, and **Prosser LA**. Projected Health Outcomes for Early Treatment Strategies of Dental Caries in U.S. children. Society for Medical Decision Making Annual Meeting, October 2020, virtual meeting.
20. DeLuca EK, Gebremariam A, Rose AM, **Prosser LA**. The Cost-Effectiveness of Routine Annual Influenza Vaccination by Age and Risk Status. Society for Medical Decision Making Annual Meeting, October 2020, virtual meeting.
21. Avanceña ALV, **Prosser LA**. What Health Equity Concerns Can be Incorporated in Cost-effectiveness Analyses? A Critical Examination of the Literature. Society for Medical Decision Making Annual Meeting, October 2020, virtual meeting.
22. Chen HF, Hutton DW, Lavieri MS, **Prosser LA**. The Costs and Health Outcomes of Newborn Screening and Treatment of Spinal Muscular Atrophy. Society for Medical Decision Making Annual Meeting, October 2020, virtual meeting.
23. Doan TT, Rose AR, Gebremariam A, Fontana M, Yanca ER, Kimmel L, Keels MA, Quinonez RB, Eckert G, Levy S, Hara A, **Prosser LA**. Simulated Health Outcomes of Dental Caries Prevention in U.S. Children. International Association for Dental Research Annual Meeting, July 2021, virtual meeting.
24. **Prosser LA**, Deluca EK, Chung G, Perroud J, Avancena ALV, Doan T, Chen HF, Janusz C, Rose AM, Suh D, Cadham C, Hutton DW. Projected Cost-effectiveness of Vaccination Against COVID-19 in Pediatric and Adult Populations. Society for Medical Decision Making Annual Meeting, October 2021, virtual meeting.
25. Kim DD, Do LA, Synott PG, Lavelle TA, **Prosser LA**, Wong JB, Neumann PJ. Developing Criteria for Health Economic Quality Evaluation (CHEQUE) Tool. Society for Medical Decision Making Annual Meeting, October 2021, virtual meeting.
26. Doan TT, Janusz C, Rose AM, Gebremariam A, Fontana M, Keels MA, Eckert G, Levy S, Hara A, **Prosser LA**. A Cost-effectiveness Analysis of Dental Caries Prevention Strategies in U.S. Children. Society for Medical Decision Making Annual Meeting, October 2021, virtual meeting.
27. Doan TT, Hutton DW, Wright D, **Prosser LA**. Universal Routine Depression Screenings for U.S. Adolescents in Primary Care: A Cost-effectiveness Analysis. Society for Medical Decision Making Annual Meeting, October 2021, virtual meeting.

28. DeLuca EK, Dalziel K, Wagner A, Wittenberg E, Rose A, **Prosser LA**. Deriving a Health State Classification System to Measure Health Utilities for Pediatric Populations Based on the PedsQL: A Confirmatory Factor Analysis. Society for Medical Decision Making Annual Meeting, October 2021, virtual meeting.
29. Cadham C, **Prosser LA**. Eliciting Preferences and Weights for Equity and Efficiency: A Methodological Scoping Review. European Health Economics Association Conference. July 2022. Oslo, Norway.
30. Cadham C, **Prosser LA**. Social Welfare Function Approaches to Evaluating Inequality Aversion: A Methodological Scoping Review. European Health Economics Association Conference. July 2022. Oslo, Norway
31. **Prosser LA**, Wagner A, Wittenberg E, Zikmund Fisher B, Rose AM, Pike J. A Discrete Choice Experiment to Compare COVID-19 Vaccination Decisions for Children and Adults. Society for Medical Decision Making Annual Meeting. October 2022. Seattle, WA.
32. Mercon KR, Rose AM, Gebremariam A, Wittenberg E, Pike J, **Prosser LA**. Measuring the effect of COVID-19 illness on health-related quality of life in adults and children. Society for Medical Decision Making Annual Meeting. October 2022. Seattle, WA.
33. Chen HF, Rose AM, Mercon K, Cousino MK, Adler J, Gadepalli S, Odetola FO, Sandberg DE, Streur C, **Prosser LA**. A Best-Worst Scaling Survey for Measuring Family Spillover Effects for Children with Complex Chronic Conditions: A Pilot Study. Society for Medical Decision Making Annual Meeting. October 2022. Seattle, WA.
34. DeLuca EK, Dalziel K, Henderson N, Wittenberg E, **Prosser LA**. Deriving a Health State Classification System to Measure Health Utilities for Children Based on the PedsQL: Using Rasch Analysis for Item Reduction. Society for Medical Decision Making Annual Meeting. October 2022. Seattle, WA.
35. Cadham CJ, **Prosser LA**. Eliciting Trade-Offs Between Equity and Efficiency: A Methodological Scoping Review. Society for Medical Decision Making Annual Meeting. October 2022. Seattle, WA.
36. Doan TT, Hutton DW, Wright D, **Prosser LA**. Natural History of Major Depression in U.S. Adolescents by Age, Sex, and Race-Ethnicity: A Simulation Model. Society for Medical Decision Making Annual Meeting. October 2022. Seattle, WA.
37. Mercon K, Rose A, Gebremariam A, Pike J, Wittenberg E, **Prosser L**. How Much Time Would Parents Give up to Prevent COVID-19 Illness in Children? Pediatric Academic Societies Annual Meeting. April 2023. Washington DC.
38. Cadham CJ, Rose A, Mercon K, Wittenberg E, **Prosser LA**. Impact of the Age of an Ill Individual on Family Spillover Effects. Society for Medical Decision Making Annual Meeting. October 2023. Philadelphia, PA.
39. Kim DeLuca E, Dalziel K, Wittenberg E, Rose AM, **Prosser LA**. Challenges in Valuing Child Health Using Time Trade-Off: Unwillingness to Trade Children's Length of Life. Society for Medical Decision Making Annual Meeting. October 2023. Philadelphia, PA.
40. Kim DeLuca E, Dalziel K, Wittenberg E, Rose AM, **Prosser LA**. Development of a Preference-Based Health-Related Quality of Life Measure for Children: The PedsUtil Scoring System. Society for Medical Decision Making Annual Meeting. October 2023. Philadelphia, PA.
41. Cadham CJ, Rose A, Mercon K, Wittenberg E, **Prosser LA**. Do Family Spillover Effects of Illness Vary with the Age of the Ill Individual? International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Annual Meeting. November 2023. Copenhagen, Denmark.
42. Cadham CJ, Ali S, Meza R, **Prosser LA**. Public Preferences for Improving Health Equity: A Qualitative Focus Group Study. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting. May 2024. Atlanta, GA.
43. Cadham CJ, Ali S, Meza R, **Prosser LA**. Public Preferences for Improving Health Equity in Canada: A Qualitative Focus Group Study. Canada's Drug Agency (CDA-AMC) Symposium. September 2024. Ottawa, Ontario, Canada.

44. Cadham CJ, Ali S, Meza R, **Prosser LA**. Understanding Equity-Efficiency Trade-offs for Healthcare Resource Allocation in Canada: A Best-Worst Scaling Exercise. Canada's Drug Agency (CDA-AMC) Symposium. September 2024. Ottawa, Ontario, Canada.
45. Cadham, CJ, Ali, S, Meza, R, **Prosser, LA**. Understanding Equity-Efficiency Trade-offs for Healthcare Resource Allocation: A Best-Worst Scaling Exercise. Society for Medical Decision Making Annual Meeting. October 2024. Boston, MA.
46. Rose AM, Mercon K, Gebremariam A, Pike J, **Prosser LA**. Out-of-pocket Costs, Time Burden, and Caregiver Quality of Life Associated with Pediatric Respiratory Syncytial Virus. Society for Medical Decision Making Annual Meeting. October 2024. Boston, MA.
47. Christopher CJ, Rose A, Mercon K, Wittenberg E, **Prosser LA**. Framing Effects for Response Choices in a Time Trade-Off Survey. Society for Medical Decision Making Annual Meeting. October 2024. Boston, MA.
48. Cadham, CJ, **Prosser, LA**. Prioritizing Healthcare Resource Allocation by Age: Results from a Nationally Representative Survey of US Adults. Society for Medical Decision Making Annual Meeting. October 2024. Boston, MA.
49. Mellott CE, Chen HF, Bhatnagar D, **Prosser LA**. Assessing Family-Level Effects in Economic Evaluations: A Scoping Review of Public Health Interventions to Improve Mental Health. Society for Medical Decision Making Annual Meeting. June 2025. Ann Arbor, MI.
50. Cadham, CJ, Meza, R, Ali, S, **Prosser, LA**. An Equity-Informative Cost-Effectiveness Analysis of E-Cigarettes for Smoking Cessation. Society for Medical Decision Making Annual Meeting. June 2025. Ann Arbor, MI.
51. Kim DeLuca E, Dalziel K, Wittenberg E, Rose AM, **Prosser LA**. Constructing the PedsUtil Scoring System Using a Discrete Choice Experiment. Society for Medical Decision Making Annual Meeting. June 2025. Ann Arbor, MI.
52. Darwar R, Rose A, Gebremariam A, Reeves SL, **Prosser LA**. Cost Projections for Universal Purchase of Pediatric Vaccines in Michigan, 2025. Pediatric Academic Societies. April 2026. Boston, MA.
53. Wagner AL, Rose AM, Ji M, Bhatnagar D, **Prosser LA**. Understanding Parent Preferences for Influenza–COVID-19 Combination Vaccines in the US: Evidence from a Discrete Choice Experiment. Pediatric Academic Societies. April 2026. Boston, MA.
54. Darwar R, Rose A, Shah D, **Prosser LA**. Assessing the Value of Lost Schooling Due to Illness Among Children in the United States. International Society for Pharmacoeconomics and Outcomes Research. May 2026. Philadelphia, PA.
55. Cadham, CJ, Ali, S, Meza, R, **Prosser, LA**. Developing Direct Equity Weights for Cost-Effectiveness Analysis: Results from a US-Based Discrete Choice Experiment. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting. May 2026. Philadelphia, PA.